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 Germline genetic modification is possible in animals, but not yet in humans.  If certain 
technical obstacles were overcome, human germline genetic modification (HGGM) could 
allow human beings to create permanent heritable genetic changes in their descendants by 
changing the genetic makeup of human eggs or sperm, or human embryos at the earliest 
stages.
 
For many decades, the technical barriers to HGGM have seemed insurmountable.  
Today, however, advances in human reproductive technologies, stem cell science, and 
animal genetic modification have brought the possibility of HGGM much nearer than it 
has been before.  The Genetics and Public Policy Center believes it is time for renewed 
consideration of this controversial subject.  This report, Human Germline Genetic 
Modification: Issues and Options for Policymakers, analyzes the scientific, legal, regulatory, 
ethical, moral, and societal issues raised by genetic modification of the human germline, 
provides data about the American public’s views about HGGM, and explores possible 
policy approaches in this area.
Science
Germline genetic modification is possible in laboratory animals, and some techniques 
could be translated for use in humans although none has been tried. Scientists are able to 
replace a faulty gene with a “normal” copy in mouse embryonic stem cells, then introduce 
those stem cells into an early mouse embryo where they can give rise to genetically 
modified sperm or eggs. The next generation of mice that results from the modified 
sperm or eggs will contain the “normal” copy of the gene.  It is now possible to replace a 
gene in human embryonic stem cells, overcoming a huge obstacle to HGGM. In addition, 
scientists have been able to derive genetically modified sperm directly from mouse stem 
cells.  Together, these developments suggest that HGGM may not be as far off as we 
thought even five years ago. 
While advances in these techniques have been driven by more general research goals 
widely viewed as valuable, and not the pursuit of HGGM specifically, these discoveries will 
catapult us over what were understood to be the principal technical obstacles to HGGM.  
Safety
Serious consideration of safety is and has been of utmost importance in any 
deliberation about HGGM.  In animal research, many germline genetic modification 
approaches can introduce unwanted mutations that can lead to severe developmental 
outcomes, even death. 
Most safety risks of HGGM would be to the resulting child. The proposed techniques 
for HGGM involve extensive manipulation of stem cells, eggs, sperm, or embryos in the 
laboratory prior to introduction into a woman’s uterus. Such manipulation alone could 
alter the growth and development of the fetus in ways that are not yet well understood, 
resulting in health problems that in many cases could be lethal.
There is a clear need for more animal research and better data, although it is less clear 
how much and what it would need to show.  Many questions exist about how to measure 
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the risks and benefits of HGGM.  And although it is a basic tenet of medical practice that 
patients receiving medical treatment must provide informed consent, opinions are divided 
as to whether and when the consent of the true “patients” — the future child and future 
generations — could and should be assumed. 
Scenarios
HGGM may become more technically feasible in the future.  The question remains 
whether and for what purpose HGGM would be attempted. Many first applications could 
be imagined for HGGM and the technical feasibility and perceived demand are different 
for each.  An example of a technically more feasible use of HGGM with low demand 
would be its use to prevent recessive genetic disease such as cystic fibrosis.  This is more 
technically feasible because the single-gene mutations have been identified.  However, 
since these diseases can be avoided by other already existing techniques, such as PGD, 
the perceived demand for using HGGM would be low.  An example of a technically less 
feasible use of HGGM with unclear demand would be its use to enhance traits such as 
intelligence or strength.  This is less technically feasible because the genetics behind these 
traits are largely unknown.  The perceived demand is unclear because of the many ethical 
questions surrounding the use of HGGM for enhancement.  In contrast, there may be 
fewer ethical objections to — and more demand for — using HGGM to enhance human 
health, to provide a “vaccine” against HIV for example.  Feasibility would depend on both 
an understanding of the genetic disease at issue and the overall development of safe and 
efficient methods for HGGM.  A table analyzing eight possible scenarios for HGGM is 
presented in the report.
Public Opinion
Until now, the most sustained and visible deliberations about HGGM have been within 
elite governmental commissions or academic institutions.  Frequently, these groups 
have called for increased public input in the discussion, but there has been little public 
engagement in the issue outside of the extreme portrayals of HGGM by Hollywood or the 
popular press.  As a result, little has been known about the views of the general public.  
In order to learn more about what the American public knows, thinks, and feels about 
HGGM and other reproductive genetic technologies, the Genetics and Public Policy 
Center recently conducted a broad survey of 4,834 Americans.  Our data show significant 
interest in HGGM as a potential means for avoiding serious genetic disease.  However, 
concerns were expressed about how safe the technology would be, who would have access 
to it and who would not, and the impact of HGGM on society as a whole.
Ethics
The purposes for which HGGM might be attempted vary, from “fixing” a genetic 
mutation before an individual is born to enhancing children with socially desirable 
traits such as athletic skill or intelligence. Views differ as to which purposes are ethically 
acceptable and whether it is possible to meaningfully distinguish, for example, between a 
“therapeutic” use of HGGM on the one hand and an “enhancement” use on the other.  
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A vast array of ethical issues arises from HGGM.  HGGM raises both the specter of 
humans “playing God” and questions about whether such interventions in nature would 
change the human gene pool, ultimately affecting the species as a whole.  There are fears 
that HGGM will negatively affect human dignity and attitudes towards those living 
with disabilities, casting people as “problems” that could have been avoided and putting 
pressure on families to have genetically “perfect” children.   
Some question whether HGGM would start society on a slippery slope to a modern 
version of eugenics, regardless of the purposes for which it would be used.  And for those 
who categorically oppose manipulation or destruction of human embryos, HGGM would 
be unacceptable under any circumstances because it would involve one or both for the 
foreseeable future.  
Oversight
In the United States, both the Food and Drug Administration (FDA) and the 
Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health 
(NIH) play a role in current federal oversight of HGGM.  FDA has indicated that it 
would treat any proposals for HGGM the same way it treats proposals for somatic gene 
modification, and require an investigational new drug application (IND) to be filed before 
the technology may be attempted in humans.  It is unclear what criteria FDA would use to 
evaluate such an application.  At the present time, the RAC has indicated that it will not 
consider any proposals for HGGM.  
Options
An array of policy approaches is available for future oversight of HGGM.  Policymakers 
and the public may consider a direct ban of HGGM; increased oversight with an eye 
towards safety, ethical use, or both; or promotion of HGGM by providing additional 
resources for relevant research.  International laws, United States law and regulation, and 
voluntary self-regulation by scientists are some of the approaches that are described, along 
with the advantages and disadvantages of each.  
 
Although HGGM remains on the distant horizon, technologic advances are bringing 
HGGM from the imaginable to the possible. Thus it is time to consider the difficult 
questions about HGGM.  An enriched and expanded discussion that includes both experts 
and the public offers an opportunity to share information and understanding about the 
underlying values and concerns that inform our individual and collective perspectives on 
HGGM.  Such an approach ultimately will lead to thoughtful and robust public policies.
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Human Germline Genetic 
Modification (HGGM) refers to 
techniques that would attempt to 
create a permanent inheritable  (i.e. 
passed from one generation to the 
next) genetic change in offspring 
and future descendants by altering 
the genetic makeup of the human 
germline, meaning eggs, sperm, 
the cells that give rise to eggs and 
sperm, or early human embryos. 
For many decades, the technical 
barriers to HGGM have seemed 
insurmountable.  Thus, discussions 
of HGGM have focused on the 
correctness of the ends associated 
with HGGM rather than the 
feasibility of the means.  Some 
have viewed HGGM as having the 
potential for species perfection, 
while others have condemned the 
concept as an attempt to usurp 
God by making “man his own self-
creator.” 1
Two recent advances in stem 
cell research suggest that the 
technological barriers may soon 
be overcome. Scientists recently 
have created genetically modified 
mice by genetically modifying 
the cells that give rise to sperm, 
and using these resulting sperm 
for fertilization.2,3 In addition, 
scientists have genetically modified 
human embryonic stem cells.4 
These techniques overcome 
what were long regarded as 
impenetrable technical barriers, 
bringing the possibility of HGGM 
much closer.  Therefore, the time 
is right for a new public discussion 
about whether, when, and how 
HGGM research should proceed.
This report, Human Germline 
Genetic Modification: Issues 
and Options for Policymakers, is 
intended to facilitate informed 
public discussion of HGGM. It 
addresses the scientific, legal, 
regulatory, ethical, moral, and 
societal issues raised by genetic 
modification of the human 
germline and lays out an array of 
possible policy approaches that 
could be adopted for HGGM 
research. It also includes a sample 
of recent public opinion research 
conducted by the Genetics and 
Public Policy Center on this topic. 
This report does not address issues 
related to chimeras (produced 
by mixing cells from different 
humans or mixing human and 
animal cells) or wholesale genome 
replacement, such as somatic cell 
nuclear transfer.5
In previous work, the Center 
has addressed other reproductive 
genetic technologies, including 
carrier testing, prenatal genetic 
testing, and preimplantation 
genetic diagnosis (PGD), which 
enables prospective parents to 
select embryos with certain 
genetic characteristics.6 In many 
cases, these technologies could 
be used to accomplish the same 
goals as HGGM.  Some of the 
ethical, safety, and social issues are 
common to all the technologies.  
For example, reproductive genetic 
testing and HGGM raise similar 
concerns about the impact of these 
technologies on relationships 
between parents and children and 
on society’s views of and support 
for people with disabilities.
However, HGGM raises unique 
concerns because it seeks to alter 
the genetic makeup of future 
generations. Some worry about 
the significant health risks, many 
unforeseeable, which would be 
imposed on generations to come, 
and about the fact that these 
individuals could not consent 
to the procedure that imposed 
this risk. Others worry that the 
intentional manipulation of the 
genome to produce changes that 
might not have arisen otherwise 
will have a negative effect on the 
overall gene pool of the human 
species. 
In 2004, the Genetics and 
Public Policy Center convened a 
meeting, “Babies By Design: Policy 
Options For Human Germline 
Genetic Modification” to review 
the state of the science and explore 
an array of questions and concerns 
relating to HGGM. Conference 
invitees (listed at the end of this 
report) were selected to represent 
a range of disciplines and reflect a 
variety of perspectives, and their 
contributions were invaluable to 
the development of this report.  
We are grateful to the participants, 
many of whom have reviewed 
drafts of this report, for being 
so generous with their time and 
expertise.  Please note that meeting 
participants do not necessarily 
agree with or endorse this report.  
The Genetics and Public Policy 
Center assumes full responsibility 
for the report and its contents.
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Genetics
Understanding the possible 
technical approaches to 
human germline genetic 
modifi cation (HGGM) requires 
an understanding of some basic 
genetic concepts. 
An individual’s genetic makeup, 
known as his or her genome, is 
the complete set of genes that are 
spelled out in DNA. Th e human 
genome contains 20,000-25,000 
genes.
Most of the human genome is 
contained in a structure within 
the cell called the nucleus, and 
is referred to as nuclear DNA 
(Figure 1). Nuclear DNA is 
packaged into 46 chromosomes, 
23 of which came from the 
mother’s egg, and 23 from the 
father’s sperm. When egg and 
sperm join upon fertilization, the 
resulting cell, known as the zygote, 
contains the full complement 
of 46 chromosomes (Figure 2). 
Th e single cell zygote divides 
repeatedly, becoming fi rst an 
embryo, then a fetus. Every time 
a cell divides, the entire genome 
– all 46 chromosomes – is copied 
so that the same information is 
contained in the resulting cells. 
Nearly all cells in the body – also 
known as somatic cells - contain 
46 chromosomes. Eggs and sperm, 
which are called germline cells, 
contain only 23 chromosomes.
In addition to the nuclear 
DNA, a small portion of the 
human genome is found in 
structures within the cell called 
mitochondria. Mitochondrial 
DNA or mtDNA (Figure 1) 
contains only a few genes. Unlike 
nuclear DNA, almost all of a 
person’s mitochondria – and the 
mtDNA – comes from the mother’s 
egg (Figure 2). 
Genes and Disease
Th e genomes of any two people 
are 99.9 percent identical. Th e 





























Figure 1: DNA and Cell Structure
Most of the DNA in a cell is packaged into chromosomes that are contained in the 
cell’s nucleus. A small amount of DNA is contained in the mitochondria, which are 
found outside the nucleus in the cytoplasm. DNA consists of four chemical subunits 
called nucleotides – abbreviated A, T, C, G – which hold the strands together in the 
DNA double helix. Genes are specifi c segments of nucleotide sequences along the 
DNA double helix that contain instructions for making specifi c proteins. 
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sequence between individuals 
makes each person genetically 
unique. Th ese diff erences in DNA 
sequence oft en are referred to as 
genetic variations. Most genetic 
variations carry no harmful 
eff ects. Some variations, however, 
can cause disease or increase 
one’s risk of developing disease. 
A variation as small as one 
nucleotide in the DNA sequence 
can disrupt a gene severely; 
these deleterious alterations in 
DNA sequence are called genetic 
mutations. Genetic conditions 
such as Huntington disease, cystic 
fi brosis, or sickle cell disease are 
caused by mutations in single 
genes.
Th ere are two copies of every 
gene (except those on the X and Y 
chromosomes) in each cell – one 
copy came from the mother’s 
egg and the other copy from the 
father’s sperm. For conditions 
known as recessive genetic 
disorders, such as cystic fi brosis 
or sickle cell disease, one develops 
the disease only if both copies 
of the gene contain a mutation. 
If one copy of a gene contains a 
mutation and the other copy does 
not, the person does not develop 
the disease; instead he or she is 
called a carrier. When two carriers 
— people who carry a mutation 
for the same recessive disorder 
— have children, each child has a 
25 percent chance of receiving two 
copies of the mutation, one from 
each parent, and developing the 
disease. For conditions known as 
dominant genetic disorders, such 
as Huntington disease, a mutation 
in only one copy of the gene is 
needed to cause the disease. Each 
child of a parent with Huntington 
disease has a 50 percent chance of 
inheriting the dominant mutation 
and developing the disease. 
Some single gene alterations 
do not necessarily cause a disease 
but instead increase the risk 
of developing that disease. For 
example, women who carry 
alterations in the BRCA1 or 
BRCA2 genes have about an 80 
percent risk of developing breast 
cancer by age 70 as well as an 
increased risk of developing 
ovarian cancer. Men who carry 
alterations in BRCA1 or BRCA2 
likewise are at increased risk for 
breast, prostate, and other cancers. 
But some men or women who 
carry genetic alterations in BRCA1 
or BRCA2 never develop cancer. 
Furthermore, the severity of a 
disease or the stage of life at which 
the disease may develop generally 
cannot be predicted based on the 
presence of a genetic alteration.  
Not all genetic conditions result 
from mutations in single genes. 
Some genetic conditions result 
from chromosomal abnormalities, 
where a person carries too many 
or too few chromosomes, or 
chromosomes that are missing 
or carry extra segments of DNA. 
For example, an extra copy of 
chromosome 21 causes Down 
syndrome. Many chromosomal 
abnormalities result in pregnancy 
loss or stillbirth, whereas others 
cause birth defects, developmental 











Figure 2: Human Reproduction
When a sperm containing 23 chromosomes from the father fertilizes an egg 
containing 23 chromosomes from the mother, a single cell containing 46 
chromosomes, called a zygote, is formed. The zygote divides to give rise to an 
embryo containing two cells, then four, and so on, eventually developing into a fetus.
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Lastly, some health conditions 
are caused not by mutations in 
a single gene but rather involve 
alterations in many genes and the 
interaction of those genes with 
the environment, which is not 
well understood. These conditions 
frequently are referred to as 
multifactorial diseases. Examples 
include heart disease, diabetes, 
asthma, and most cancers.  
Genetics and Reproductive 
Technologies 
New reproductive technologies 
have developed alongside an 
increased understanding of 
the roles genes play in disease. 
Preimplantation genetic diagnosis 
(PGD) combines genetic testing 
and in vitro fertilization (IVF). 
IVF involves collecting eggs 
from a woman, fertilizing the 
eggs with sperm in a petri dish, 
and transferring the resulting 
embryo(s) to a woman’s uterus.  
PGD typically involves removing 
one or two cells from an embryo 
two to four days after fertilization, 
extracting DNA from these cells 
and testing the DNA for a specific 
genetic alteration or chromosome 
abnormality. Embryos free of 
the genetic disease being tested 
for or possessing desired genetic 
characteristics are selected for 
transfer into the woman’s uterus.6
Germline Genetic Modification 
If and when it occurs, human 
germline genetic modification 
would involve introducing a new 
genetic sequence into a person’s 
germline cells that could be 
passed to future generations. The 
techniques that might be used 
in humans draw from successful 
germline genetic modification 
studies in animals, human stem 
cell research, and human somatic 
gene therapy techniques where 
non-heritable genetic changes are 
made in an attempt to cure or treat 
disease. 
In theory, there are several 
ways to modify a person’s genome. 
An entire gene or part of a gene 
could be inserted somewhere 
into the genome. This inserted 
DNA sequence, sometimes 
called a transgene, could be a 
normal copy of a resident gene. 
Introducing a normal copy of 
that gene could compensate 
for the nonfunctioning or 
malfunctioning resident gene. 
Instead of introducing a whole 
gene, a transgene could be a 
segment of DNA that affects the 
function of a resident gene to 
turn it on or off. Alternatively, the 
transgene could introduce a whole 
new, and previously non-existent 
gene function into the genome. 
An example would be the gene for 
green fluorescent protein that has 
been introduced into a number of 
laboratory animals to make them 
glow.
All cells in an adult animal’s 
body develop from the zygote, the 
fertilized egg. Because germline 
genetic modification seeks to 
modify all of the cells in the adult 
body, the genetic modification 
must be introduced into the eggs 
and sperm, the precursor cells that 
give rise to eggs and sperm, or very 
soon after fertilization in a zygote 
or very early embryo.    
There are a variety of theoretical 
uses of human germline genetic 
modification.  “Therapeutic”, or 
health-related, modifications of 
the genome would seek to cure 
or ameliorate a disease in future 
generations.  “Enhancement”, or 
non-health related, uses would be 
aimed at adding or augmenting 
characteristics or traits not related 
to disease, such as muscle mass or 
height. Some uses, however, are not 
easily categorized as either therapy 
or enhancement. For example, 
germline genetic modification 
conceivably could be performed 
to confer resistance to disease, 
which might be considered both 
therapeutic and enhancement. 
Such a use may best be termed 
preventative.13
Science 
Cloning:  Extreme genetic 
modification
Another technique that 
genetically modifies the 
germline is somatic cell nuclear 
transfer (SCNT). SCNT involves 
the transfer of the nucleus of an 
adult somatic cell into an egg 
from which the nucleus has been 
removed. The resulting zygote 
could be allowed to develop into 
an embryo that is genetically 
identical to the adult who 
donated the somatic nucleus. 
Although technically the 
resulting embryo is genetically 
modified in the sense that its 
genome has been changed, this 
wholesale genome replacement 
is considered to be cloning, 
which is the subject of the 
Center’s report Cloning: A Policy 
Analysis.38
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In theory, successful HGGM 
could eradicate a genetic disease in 
a family by permanently replacing 
a gene containing a mutation with 
a normal copy of that gene. Single-
gene disorders such as cystic 
fibrosis or Huntington disease 
would be the most straightforward 
targets for HGGM because 
replacing the mutated gene should 
prevent the disease. Using HGGM 
for multifactorial diseases or to 
enhance complex traits such as 
intelligence are much less feasible 
because they involve many genes 
and many environmental factors, 
and the genetic contributors 
remain largely unknown.  
Germline Genetic Modification 
Techniques Under Study
Germline modification 
techniques have been used widely 
in mice and other species for 
many years14 and these methods 
potentially could be employed 
in humans some day. Genetic 
modification in humans has 
been limited to somatic cell 
gene therapy where genes are 
introduced into target cells of 
the body in an effort to correct 
or ameliorate an existing disease 
or condition in that individual. 
Similar techniques might be 
adaptable for human germline 
genetic modification. However, 
several significant technical 
barriers must be overcome in order 
for the human germline to be 
successfully modified. 
Delivering a gene or any DNA 
segment into a cell requires a 
means of getting the gene of 
interest into the target cell. The 
three principal methods for 
delivering genes into a target cell 
are using a virus carrying the 
gene of interest to infect a cell, 
introducing a gene of interest into 
a cell via a non-viral mechanism, 
and introducing an entire artificial 
chromosome containing a gene, 
or many genes, into a cell.  Each 
approach has advantages and 
disadvantages, and each approach 
varies in its likelihood of being 
applied successfully to human cells 
for HGGM.  
Twenty-five years of research 
in somatic gene transfer have 
yielded some success in using viral 
vectors to deliver a gene of interest 
into target cells.15,16,17 The gene of 
interest is placed in a virus that has 
been modified such that it infects 
cells but can no longer cause 
disease. This engineered virus then 
infects the target cell and the viral 
DNA usually inserts itself and the 
gene it carries somewhere into the 
genome.
A gene also can be delivered 
into a cell by a non-viral method. 
Four non-viral methods of gene 
delivery are: direct microinjection 
of DNA segments carrying the 
gene of interest into the nucleus of 
the cell; electroporation, whereby 
an electrical current is applied to 
the cell, causing it temporarily to 
Genetically modified humans living among us? 
It has been theorized that “faulty” ooplasm may contribute to infertility 
in some couples. To compensate for this, ooplasm from a healthy donor 
egg – including mitochondria and mtDNA but not the nucleus or 
nuclear DNA – has been transferred into the eggs of infertile women. 
Approximately 30 babies worldwide have been born following ooplasm 
transfer.7 These cases have been called the first examples of HGGM 
because the resulting child’s mtDNA is a mixture of both the mother’s 
and the ooplasm donor’s mtDNAs.7 This mixture of mtDNA is known 
as mitochondrial heteroplasmy.7,8,9 Since mitochondria are passed solely 
through the mother, a female child with mitochondrial heteroplasmy 
may transmit both types of mtDNA to her offspring, leading to a 
heritable, germline genetic modification (Figure 3).
Ooplasm transfer potentially could be used also as a form of gene 
therapy to attempt to treat or cure mtDNA-related disease.10 
Human eggs also can be genetically modified by a process called 
pronuclear transfer. For pronuclear transfer, the pronuclei – the egg 
nucleus and sperm nucleus – from a fertilized egg are removed and 
placed in a donor egg that has had its own nucleus removed. Like 
ooplasm transfer, the resulting child would carry genetic material from 
three people – nuclear DNA from the mother and father, and mtDNA 
from the donated egg.11 No live born child has resulted from this 
procedure. One triplet pregnancy was reported but there were no live 
births.  DNA studies on the fetuses confirmed the presence of maternal 
and paternal nuclear DNA as well as mtDNA from the donor.12
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open small holes in its outer layer 
to allow entry of the DNA vector 
carrying the gene of interest; 
lipofection, whereby the vector 
carrying the gene of interest is 
packaged into a fatty substance 
that can easily pass through 
the cell’s outer layer and release 
its contents into the cell; and 
transposable elements, which are 
segments of DNA that can insert 
themselves into chromosomes. 
And, although most gene delivery 
studies have focused on targeting 
the nuclear genome, it may be 
possible also to introduce genes 
into the mitochondrial genome.18,19
Researchers also are 
experimenting with the possibility 
of using artifi cial human 
chromosomes to introduce genes 
of interest into target cells for 
somatic gene therapy.20 Artifi cial 
chromosomes are larger in size 
than the typical DNA vector 
and can carry all of the genetic 
sequences necessary for a gene to 
function properly. In order to be 
eff ective in germline modifi cation, 
however, an artifi cial chromosome 
would have to exist alongside the 
standard 46 chromosomes in each 
cell and be copied and transmitted 
reliably when a cell divides into 
two. Artifi cial chromosomes have 
shown varied success in other 
organisms such as yeast, bacteria, 
and some mammalian cells.21 
However, artifi cial chromosomes 
have not yet proven to be feasible 
in humans.20 If this technology 
could be perfected for somatic gene 
transfer, it might be possible to use 
human artifi cial chromosomes in 
HGGM as well. 
Germline genetic modifi cation 
could be performed in egg or 
sperm cells or the cells that 
give rise to eggs and sperm, the 
gametocytes. Recent studies in 
mice have shown that mouse 
ovaries continue to produce 
eggs throughout the mouse’s 
reproductive lifespan.22 If true 
in humans, it may be possible to 
genetically modify a woman’s 
gametocytes by targeting her 
ovary. Eggs produced by that 
ovary would in theory contain that 
genetic modifi cation. Likewise, 
male gametocytes in the testis also 
could be targeted so that it would 
produce genetically modifi ed 
sperm. Some early experiments in 
animals have been successful23,24,25  
but this approach has not been 
tried in humans.  
Germline genetic modifi cation 
also could be performed in an 
embryo, but it must occur at a 
very early stage of development 





Donor Egg Recipient Egg Fertilization
Figure 3: Ooplasm Transfer
The ooplasm of the donor egg is transferred into the recipient egg. Since this process transfers mitochondria, the recipient egg 
now contains mitochondrial DNA from two different people (donor and recipient). After this egg is fertilized and transferred into 
a woman’s uterus, the resulting baby carries DNA from three people – nuclear DNA and mtDNA from the mother, nuclear DNA 
from the father, and mtDNA from the ooplasm donor.
Science 
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stage – in order to ensure that the 
cells that will develop into the egg 
or sperm carry the gene of interest. 
Genetic modification of older 
embryos (consisting of hundreds 
of cells) has been successful 
in many animal models by 
introducing genetically modified 
stem cells into the developing 
embryo. However, because not all 
cells of the resulting embryo are 
genetically modified, the germline 
cells may remain unmodified. 
This condition is referred to as 
mosaicism. Mosaicism also can 
occur if the introduced gene 
becomes lost in some cells of 
the animal when the cells divide 
during development.26 If the 
germline cells in a mosaic animal 
are not genetically modified, the 
modification will not be passed to 
the next generation.
Stem cells are another potential 
target for HGGM. Human 
stem cells can be isolated from 
many different tissues: Human 
embryonic stem cells (ES cells) 
are derived from the cells of a 
young embryo; embryonic germ 
ridge cells are isolated from young 
human fetuses; and adult stem 
cells can be isolated a number 
of tissues. Stem cells have the 
ability to develop into many 
cell types found in the adult 
human body.2,27,28,29 Stem cells 
offer significant advantages as 
targets for genetic modification. 
For example, they can grow 
indefinitely while remaining 
undifferentiated, meaning they do 
not develop into specialized cell 
types like muscle or skin.  Because 
they can be grown in a petri dish 
in a laboratory, stem cells can 
be genetically manipulated and 
subjected to genetic tests to verify 
that the genetic modification 
is present. Mouse embryonic 
stem cells have been modified 
successfully in this manner.30,31
Recent significant advances in 
mice involve genetically modifying 
Is human germline genetic modification technically realistic?
In 2000 the American Association for the Advancement of Science 
(AAAS) released a report called Human Inheritable Genetic 
Modifications: Assessing Scientific, Ethical, Religious and Policy Issues 
that concluded human germline genetic modification “cannot presently 
be carried out safely and responsibly on humans. Current methods 
for somatic gene transfer are inefficient and unreliable because they 
involve addition of DNA to cells rather than correcting or replacing a 
mutated gene with a normal gene. They are inappropriate for human 
germline therapy because they cannot be shown to be safe and effective. 
A requirement for inheritable germline modification, therefore, is the 
development of reliable gene correction or replacement techniques.”34
Two recent advances have brought us significantly closer to the 
possibility of germline genetic modification in humans. The first 
advance is that gene targeting by homologous recombination – replacing 
a mutated gene with a “normal” copy – recently has been demonstrated 
in human embryonic stem (ES) cells.4
The second advance is getting stem cells to differentiate into germline 
cells – either sperm or eggs. Adult mouse sperm precursor stem cells 
have been isolated, genetically modified by gene targeting and coaxed 
into becoming mature sperm.2,3 These genetically modified sperm have 
been used for successful fertilization to give rise to genetically modified 
mice. 
Mouse ES cells have also been coaxed into producing eggs35 and 
sperm36,37 (Figure 4). These sperm have been used for fertilization and 
developed into mouse embryos.4 It remains unknown if these embryos 
can give rise to live born mice, but further research might support this 
approach as a viable technique for germline genetic modification.
Gene targeting studies in human ES cells will continue and likely be 
improved in the process of studying the molecular basis of human 
disease and in developing new treatments. Similarly, deriving functional 
sperm or eggs from stem cells also will be pursued as a means of 
developing genetically modified model organisms for biomedical 
research. While advances in these techniques will be driven by relatively 
uncontroversial research goals, and not the pursuit of HGGM, they 
effectively will catapult us over what were identified heretofore as the 
principle technical obstacles to HGGM.  
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adult sperm precursor stem cells 
and causing them to develop into 
mature sperm, which then are 
used to fertilize eggs, giving rise to 
genetically modifi ed mice (Figure 
4).  In addition, mouse embryonic 
stem cells have been modifi ed, 
coaxed into developing into 
sperm, and used to create mouse 
embryos.32 
Germline genetic modifi cation 
also could be performed in stem 
cells that could then be implanted 
into a developing embryo. 
Although this has not been done 
in humans, it is used frequently in 
mouse studies.30
Some major technical challenges 
in gene modifi cation involve 
uncontrolled insertions of the new 
gene or genes into the DNA of the 
target cell; improper gene function 
of the inserted gene; accidental 
mutation of a healthy gene; failure 
to remove the original, mutated 
gene; and separation of the newly 
introduced gene from the mutated 
gene. 
With many methods of 
delivering a gene to a target cell, 
genes tend to be introduced at 
random locations in the genome. 
Th e inability to specifi cally and 
effi  ciently target a specifi c site 
of the genome poses a number 
of problems. First, accidental 
insertion of a gene into a normal 
resident gene can disrupt its 
function, a problem called 
insertional mutagenesis. Th e 
risk of insertional mutagenesis is 
diffi  cult to predict but it occurs at a 
signifi cant rate in animal studies.14 
Insertional mutagenesis also 
has occurred in human somatic 
gene therapy clinical trials.33 
Second, random insertion of the 
introduced gene also can result in 
abnormal expression of the added 
gene.  Th ird, too many copies of a 
gene also can be inserted, leading 











Figure 4: Sperm and eggs derived from ES cells
Embryonic stem cells are able to develop into all types of cells in the body such as blood, muscle, and neurons. Recently, mouse 
embryonic stem cells have been coaxed to develop into egg or sperm precursor cells – germline cells. These egg or sperm precursor 
cells can develop into mature eggs or sperm. Deriving germline cells from human embryonic stem cells has not been reported.
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random insertion could result in 
the introduced gene being located 
on a diff erent chromosome from 
the mutation-containing resident 
gene.   And, because chromosomes 
are shuffl  ed and separated from 
each other during formation of egg 
and sperm, this shuffl  ing could 
lead to the introduced gene ending 
up in a diff erent egg or sperm cell 
from the mutated resident gene, 
which would lead to the disease 
reappearing in future generations. 
Another signifi cant limitation 
of gene delivery techniques is 
that these techniques typically do 
not remove the original, mutated 
gene. Introducing a normal 
copy of a gene aims to replace 
an existing, non-functioning, 
or malfunctioning gene. Th is 
approach could work when 
introducing a functional copy of a 
gene is all that is required for the 
desired eff ect. But certain genetic 
mutations, particularly dominant 
mutations, cannot be corrected by 
introducing a healthy copy of the 
gene. 
Th e problems associated with 
random gene insertion and the 
failure of many techniques to 
remove the original mutated 
gene could be avoided by using 
gene targeting to introduce the 
gene or segment of DNA of 
interest into a precise location on 
a chromosome in the target cell 
by a process called homologous 
recombination (Figure 5). 
Homologous recombination can 
occur between two identical or 
nearly identical segments of DNA; 
these two pieces of DNA eff ectively 
swap places with each other. If the 









Figure 5: Gene targeting by homologous recombination
A mutated gene in an embryonic stem cell – indicated by the blue dot – can be 
replaced by introducing a “normal” copy of that gene into the cell. The “normal” copy 
pairs up with the mutated copy and effectively swaps places so that the “normal” 
copy ends up in the chromosome and the mutated copy is lost.
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a mutation or alteration, gene 
targeting through homologous 
recombination could replace it 
with a normal copy of that same 
gene. Gene targeting in mice has 
been successful and usually results 
in a single copy of the gene being 
inserted into the proper place 
within a chromosome, ensuring 
relatively normal gene function.14 
Homologous recombination in 
human embryonic stem cells 
recently has been reported.4 If 
this technique can be perfected 
in humans, it could be a major 
advance for somatic gene transfer 
and remove a major technical 
obstacle to HGGM.
Science 
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Safety
Germline genetic modification 
currently poses significant 
safety risks that research has not 
adequately addressed. Most risks 
are to the resulting child. The 
proposed techniques for HGGM 
involve extensive manipulation 
of stem cells, eggs, sperm, or 
embryos in the laboratory prior 
to introduction into a woman’s 
uterus. Such manipulation alone 
could alter the growth and 
development of the fetus in ways 
that are not yet well understood.39 
If a gene fails to be inserted 
into the genome or if it becomes 
inserted but fails to function, 
the resulting child likely would 
be no worse off than he or she 
would have been without the 
attempted genetic modification.40 
However, if an introduced gene 
malfunctions or if too many 
copies are introduced, serious 
health consequences could result.40 
Likewise, the insertion of a gene 
into the wrong region of the 
genome can lead to insertional 
mutagenesis, where gene insertion 
causes a mutation in an otherwise 
normally functioning gene.41 
Animal research has shown that 
insertional mutagenesis can lead 
to severe or lethal effects to the 
developing fetus.42,43 Human 
somatic gene therapy clinical trials 
to correct the “bubble boy” disease 
known as X-SCID (X-chromosome 
linked severe combined 
immununodeficiency) resulted in 
three patients developing leukemia 
as a direct result of insertional 
mutagenesis by a viral gene 
delivery system.33 Animal research 
also has indicated that inserting 
viral DNA into the genome carries 
significant health risks.14,41
Some potential HGGM 
techniques also could put 
parents at risk. Germline genetic 
modification techniques that target 
ovaries or testes could pose risks 
to parents by damaging the cells 
that give rise to mature eggs or 
sperm.44,45 Injecting viral vectors 
into testes to genetically modify 
sperm in animals has resulted 
in male infertility.45 A similar 
outcome could occur in females as 
well.46 
The safety of germline 
genetic modification is further 
complicated by the fact that some 
problems might not be evident 
until well after the genetically 
modified child is born or reaches 
adulthood, when the problems 
already could have been passed to 
the next generation.47 Introducing 
a gene into an embryo does not 
guarantee that gene will function 
at all, much less be passed on and 
function in future generations.48 
If a genetic modification is lost, 
the disease that was corrected 
very well may re-appear in future 
generations.
Given current safety concerns, 
it remains unclear whether human 
germline genetic modification 
ever will be, or ever should be, 
developed. The potential risks 
(and potential benefits) are not 
fully understood, thus difficult 
decisions would need to be made 
about whether, and under what 
circumstances, human research 
and clinical trials would be 
tolerable.49
Scientist and regulators agree 
that safety and effectiveness 
must be demonstrated clearly in 
animal models before HGGM 
ever is attempted. However, there 
is disagreement about how safety 
should be demonstrated, how long 
the research should continue and 
what level of success should be 
required. Some observers believe 
multigenerational data from 
animals will be needed before 
human trials can begin.  Given 
that it may take sixty to eighty 
years to obtain multigenerational 
data from some animal species, 
questions exist about whether 
animal data would ever be 
sufficient to warrant human 
clinical studies.50 Another view is 
that the level of efficacy in animals 
achieved before attempting 
HGGM should be greater than 
that which typically is required 
before beginning clinical trials. 
Proponents argue that currently, 
an intervention is considered 
adequate if it works as expected 
70 percent of the time, but that 
such a standard would be far too 
low to justify attempting to create 
a child using HGGM.51 Some say 
the standard of success in animals 
should be close to 100 percent, and 
scientists must understand from 
animal models what would make 
a person an appropriate candidate 
for germline modification, in order 
to exclude from participation 
those who would be unlikely to 
benefit or would face significant 
risk.52 Some believe that HGGM 
should not occur at all until it 
is scientifically possible to both 
detect and correct the problems 
that may be introduced through 
genetic modification.52  
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Measuring Risks and Benefits 
Even if agreement were reached 
regarding the appropriate quantity 
and quality of animal data, 
attempting HGGM in humans 
nevertheless would pose potential 
harms. Animal studies cannot 
predict with 100 percent accuracy 
what will happen in humans. 
Whenever new therapeutic 
interventions are contemplated, 
researchers and regulators consider 
the potential risks and benefits 
in deciding whether to proceed. 
Some have argued that HGGM 
requires a risk/benefit analysis no 
different from that applied to any 
other proposed therapy.53 Others, 
however, counter that the usual 
risk/benefit calculus is insufficient 
for the evaluation of HGGM. 
Both the magnitude and 
likelihood of potential adverse 
outcomes from HGGM would 
need consideration. However, 
while some risks of attempting 
HGGM will be identified and 
quantified, the severity of some 
outcomes likely is to be variable, 
and some adverse outcomes simply 
will not be foreseen. 
Some argue that consideration 
of risks must include potential 
harms that may be experienced 
by unspecified future generations.  
Some also argue that consideration 
of risks should not be limited 
to potential physical harms but 
should encompass the risk of 
ethical and societal harms as well. 
However, the amount of weight 
that should be given to that risk 
when compared to a potential 
near-term benefit to a specific 
person is difficult to determine. 
There also is disagreement 
concerning what should be 
considered a benefit.  Whether 
and to what extent HGGM would 
provide benefits will depend on 
both objective and subjective 
factors, including the expected 
outcome of the modification, 
why it is being attempted, and 
how one views the impact of 
the modification on the life 
of the future child and future 
generations.
Risk/benefit calculations 
typically include a consideration 
of alternatives – a high risk, 
potentially life-threatening therapy 
may be justified for a dying patient 
with no treatment alternatives 
but not justified for a mild or 
chronic disease for which there 
are alternative treatments.  In the 
case of HGGM, however, there 
is disagreement regarding the 
alternatives against which HGGM 
should be compared, and how 
the risks and benefits should be 
measured. 
 
Some say the new technology 
must be shown to be no more 
risky than the normal process 
of conception and birth.54 
Another view is that the risks of 
germline interventions for future 
generations “should be no greater 
than their risks of being born with 
the genetic condition at issue.” In 
other words, the risks to the child 
of attempting HGGM should, at 
worst, leave the child no worse 
off than if the child were born 
with the genetic disease HGGM is 
targeting.55
On the other hand, law 
professor John Robertson has 
made the argument that the risks 
of new reproductive technology 
should not be compared to 
risks faced by children born 
after traditional reproduction.  
According to Robertson, the 
relevant question is whether 
the person born after the use of 
reproductive technology is better 
off than if he or she were never 
born.  This view is based on the 
assumption that existence is in 
most if not all cases preferable 
to non-existence.56 However, 
others contend if HGGM involves 
modifying an embryo, then the 
child already exists, albeit as an 
embryo.  The alternative to HGGM 
for these future children is not 
non-existence but rather continued 
existence in an unmodified state. 
Therefore, prospective parents 
would be putting future children 
(as well as future generations) 
at greater risk by using HGGM 
than they would without the 
technology.55
Given that there are often 
alternatives to HGGM, many 
believe it would be a rare case 
in which the benefits of HGGM 
would outweigh the risks. 
Currently, families seeking to 
prevent passing a heritable single-
gene disorder to their offspring 
have several options including 
PGD, the use of donor eggs or 
sperm, and in some cases, somatic 
gene transfer or non-genetic 
therapies once the child is born.57 
Attempting HGGM for a health-
related use when alternatives are 
available would be viewed less 
favorably than cases where HGGM 
is the only possible option.58 
Human Germline Genetic Modification: Issues and Options for Policymakers 23
One possible model for 
assessing risks and benefits is the 
Federal Human Research Subject 
Protections, specifically those rules 
that apply to research on children. 
These federal regulations require 
consideration of the circumstances 
of the children under study, the 
magnitude of risks or discomforts 
that may result from participating 
in the research, and the potential 
benefits the research may 
provide to the child or to other 
children with the same disease or 
condition.59
Under these regulations, there 
are four possible categories of 
research:  a) Research that does 
not involve greater than minimal 
risk to the children, b) Research 
involving greater than minimal 
risk but presenting the prospect 
of direct benefit to the individual 
child involved in the study, c) 
Research involving greater than 
minimal risk and no prospect 
of benefit to the individual child 
in the study, and d) Research 
not otherwise approvable under 
one of the above categories but 
that is determined to present a 
reasonable opportunity to further 
the understanding, prevention, or 
alleviation of a serious problem 
affecting the health or welfare of 
children.59
These rules would provide some 
standards to an oversight body or 
an individual weighing the risks 
and benefits of HGGM, but how 
one performs the risk/benefit 
analysis is difficult to separate 
from one’s perspective on HGGM. 
For example, the possibility of 
risks to generations many decades 
hence may seem small to an adult 
suffering from a serious genetic 
disease who wishes to prevent 
his or her future child from 
suffering from the same disease.  
On the other hand, an observer 
concerned that HGGM will have a 
devastating impact on the human 
species may believe no “benefit” 
to an individual is so great that 
it could compensate for this risk.  
These concerns would not fit 
readily into the current human 
subjects regulations, where under 
most circumstances the risks and 
benefits are to a single child and 
harms to society are not easily 
considered.
Informed Consent 
It is a general principle of 
human subjects research that 
researchers must secure the 
voluntary informed consent of 
participants before proceeding.60 It 
is unclear what information would 
need to be provided to prospective 
parents in order to inform them 
adequately of the risks associated 
with HGGM, given that many of 
these risks are unknown. It also is 
unclear whether obtaining consent 
only from the prospective parents 
would be adequate. Because 
HGGM alters individuals who are 
not yet conceived or born, some 
might argue it would be unethical 
to ever attempt HGGM because 
the informed consent of the future 
“patients” could not be obtained.  
However, parents generally are 
authorized to consent on behalf of 
their children or future children. 
For example, many parents pursue 
genetic testing of a fetus through 
amniocentesis or other means, or 
pursue fetal surgery even though 
the fetus is unable to give consent 
for such testing or treatment.  
Children often receive treatments 
and the informed consent of the 
parent stands in for the informed 
consent of the child. However, 
although parents may have 
the right to make decisions on 
behalf of children, or even future 
children, it may be argued that 
they do not have the legal or moral 
authority to do so for generations 
to come.  
Some believe the imperative to 
obtaining informed consent from 
future children is overstated, and 
that their interests simply need 
to be considered reasonably.61 For 
example, it may be possible to rely 
ethically on parental consent in 
cases where the alternative – the 
genetic disease in question – is so 
severe (for example, suffering and 
death in very early childhood) that 
the risks of HGGM safely can be 
said to be acceptable.  
The need to conduct long-
term, possibly multigenerational, 
follow-up studies also could 
pose a challenge. Researchers 
may want prospective parents 
to agree to have their children, 
and perhaps several generations 
thereafter, studied from birth.57 
However, it would not be possible 
to guarantee participation in a 
study, as participants are always 
free to withdraw. Some have 
argued that multi-generational 
effects should be studied in 
animals but that human trials 
should follow subjects only for the 
first generation.53 There have not, 
to date, been any comprehensive 
long-term follow-up studies in the 
United States on the long-term 
health effects of other reproductive 
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technologies, such as in vitro 
fertilization and PGD.
Scenarios for HGGM 
Given current scientific 
knowledge, HGGM is widely 
viewed as unsafe to attempt in 
humans. Yet as described above, 
recent scientific developments 
suggest that HGGM may become 
more technically feasible in the 
future.  The question remains 
whether and for what purpose 
HGGM would occur.
Scientists’ willingness to 
invest the time and research to 
develop the technology may be 
limited by the many existing 
alternatives to HGGM (including 
PGD, prenatal genetic testing 
followed by termination, adoption, 
embryo or gamete donation, and 
somatic therapy).  On the other 
hand, several factors may create 
consumer demand. Prospective 
parents, those with sick children 
or genetic disease in the family, 
and patients themselves may 
create a demand for HGGM. For 
some patients, any possibility 
of treatment or cures is worth 
pursuing.62,63 The fame and fortune 
HGGM could bring to scientific 
and medical pioneers and the 
companies that back them may 
spur interest in the technology.51 
And although there may be 
alternatives to “therapeutic” 
uses, the potential to “enhance” a 
future child, rather than prevent 
a heritable disease may create its 
own consumer demand.64
The chart at right examines 
specific circumstances under 
which HGGM could occur, and 
compares the technical feasibility 
of HGGM and possible consumer 
demand for HGGM under each set 
of circumstances.
Table 1: 
Technical feasibility considers 
the extent to which the genetic 
factors at issue are known and 
can be manipulated, and whether 
the necessary technique exists or 
is foreseeable.  
Consumer demand considers 
whether alternative treatments 
are available, the number of 
people affected by the disease 
or condition, and whether the 
targeted genetic characteristic 
likely is to be viewed as a serious 
disease or as a more ethically 
problematic enhancement. 
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Table 1: HGGM Applications: Technical Feasibility and Consumer Demand
Scenario Examples Technical feasibility Consumer demand
Prevention of 
mitochondrial disease
Transfer donor ooplasm in 
order to provide unaffected 
mitochondria and mtDNA
Most feasible
Ooplasm transfer and 
pronuclear transfer have 
been performed in humans. 
Less demand 
Mitochondrial disease is 
extremely rare.
Genetic vaccine Confer genetic resistance to 
HIV infection (e.g. CCR5)
Moderately feasible 
Some genes have been 
identified; feasibility is 






Prevention of recessive 
disease with two 
affected parents
Prevent cystic fibrosis 
in child of two affected 
parents.
Moderately feasible 
Genes have been identified; 
feasibility is dependent 
on efficient genetic 
modification techniques.  
Less demand
Extremely rare cases.  Adoption, 
donor gametes or embryos are 
alternatives.
Prevention of late onset 
dominant disease with 
homozygous parent
One parent has two copies 
of BRCA1 mutation.
Moderately feasible
Genes have been identified; 
feasibility is dependent 
on efficient genetic 
modification techniques.  
Less demand
Cases are extremely rare:  
homozygosity of many dominant 
disease-related gene mutation 
often has severe effects that 
preclude survival to reproductive 
age.
Prevention of recessive 
disease 
Prevent sickle cell disease, 
cystic fibrosis, thalassemia 
in children of two carriers.
Moderately feasible
Genes have been identified; 
feasibility is dependent 
on efficient genetic 
modification techniques.  
Less demand
PGD is an effective alternative.
Enhancement of physical 
characteristics, mental 
capacity or behavior
Change or add gene to 




Genetic contributors to 
these characteristics are 
unclear.  
Uncertain demand








contributors not known, 
may require use of artificial 
chromosomes.
Uncertain demand
Ethical objections to multiple 
enhancements may be 
particularly high.
Extensive changes Add armored skin, 
functional wings 
Least feasible
Genetic contributors are 
currently only imagined.
Any level of demand by parents 
is questionable.
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For decades, many have 
questioned whether human 
germline genetic modification is 
or ever could be “ethical,” however 
one defines that term.  Because 
it aims to make permanent 
changes to DNA that would affect 
generations not yet born, HGGM 
raises unique ethical issues.  
For some, the most significant 
ethical challenge stems from the 
significant safety risks outlined 
in the previous chapter.  Such 
risks are viewed as ethically 
unacceptable in the absence of 
substantial countervailing benefits. 
For others, the societal impact 
of HGGM is the paramount 
concern. Pressures to “cure” 
inherited disease in future 
descendants could change family 
relationships, particularly those 
between parents and children.  
Human germline genetic 
modification has the potential 
to create the expectation that all 
babies should be born without 
genetic health conditions, and 
might thereby decrease society’s 
tolerance for and willingness to 
support and treat those living with 
disabilities. Many have raised the 
specter that notions of equality 
and fairness would be upended 
by a technology that created 
“enhanced” children only for those 
who could afford the treatment.  
Concerns about HGGM also 
stem from deeply held religious 
perspectives on the morality of 
the techniques that would be used 
to perform HGGM.  For those 
who categorically oppose the 
manipulation or destruction of 
human embryos, HGGM would 
be ethically problematic because 
it involves one or both, at least for 
the foreseeable future.65  
In the United States, discussion 
of the ethics of human germline 
genetic modification largely has 
been confined to academic circles 
and government commissions, 
without significant input from the 
public.  This section summarizes 
many significant contributions 
to the literature on the ethical 
dimensions of human germline 
genetic modification.  It also 
describes findings from our own 




A quarter of a century ago, 
representatives of three major 
religious organizations raised 
concerns about the fundamental 
moral, ethical, and religious 
questions related to new genetic 
technology, and called upon 
President Jimmy Carter to address 
the lack of adequate oversight and 
control in this area.66 In response, 
President Carter charged the 
President’s Commission for the 
Study of Ethical Problems in 
Medicine and Biomedical and 
Behavioral Research to examine 
the social and ethical implications 
of “genetic engineering” or “gene 
splicing” – as it was then called 
– as it applied to humans.  The 
Commission considered gene 
splicing, as well as somatic cell 
and germline gene modification.  
At that time, the technique of 
gene splicing was less than a 
decade old and had been used 
only in laboratory research.  
Many concerns at that time 
revolved around the potential 
for accidental release of novel, 
genetically modified organisms 
and possible harms to humans 
and the environment. At the same 
time, many foresaw the potential 
benefits of using gene splicing and 
related technologies to alleviate 
human disease.67,68
 
The Commission’s report, 
Splicing Life: The Social and 
Ethical Issues of Genetic 
Engineering, was intended to 
stimulate long-term discussion 
rather than to provide premature 
conclusions.69 Nevertheless, 
the Commission made several 
findings and recommendations.  
The Commission concluded 
that while public anxieties were 
“exaggerated,” genetic engineering 
techniques were a “powerful new 
tool for manipulating nature” 
and a reminder of “human 
obligations to act responsibly.”70 
The Commission found that 
genetic engineering techniques 
had great potential to alleviate 
human suffering.70 However, it 
recommended that particularly 
close scrutiny be given to 
procedures that would create 
inheritable genetic changes in 
humans. Interventions aimed 
at enhancing healthy people as 
opposed to remedying genetic 
disease were seen as problematic, 
although drawing the line between 
treatment and enhancement was 
viewed as subjective.71 Responding 
to the critique that genetic 
engineering was impermissibly 
“playing God,” the Commission 
stated that while the scientific 
procedures were not “inherently 
inappropriate,” such concerns 
deserved serious attention and 
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served as “a valuable reminder 
that great powers imply great 
responsibility.”71 The Commission 
recommended that the National 
Institutes of Health extend the 
scope of its existing Recombinant 
DNA Advisory Committee 
(RAC) to examine the safety 
of applications such as human 
gene therapy, and signaled a 
profound need for an oversight 
body, preferably one that would 
include participants from 
diverse backgrounds including 
government representatives, 
scientists, industry, lawyers, 
ethicists, religious leaders, and 
members of the public.72 
Although its primary focus was 
on somatic gene modification, 
the Commission specifically 
considered the potential use 
of genetic engineering in 
germline cells. In particular, the 
Commission focused on what it 
termed “zygote” therapy, i.e., the 
potential genetic modification of 
a fertilized egg.  The Commission 
described safety concerns about 
genetic engineering and numerous 
cases where alternatives to “zygote” 
therapy might be possible.  With 
respect to ethics, the Commission 
noted that some had raised eugenic 
concerns about altering the gene 
pool to eliminate undesirable 
traits.65 
In the late 1990s, HGGM 
increasingly entered ethical 
debates as a potential variation 
of emerging attempts at somatic 
gene therapy.  In the RAC, the 
gene therapy pioneer, W. French 
Anderson, submitted two “pre-
protocols” for in utero gene 
therapy.  Although the research 
in question actually was not ready 
to move forward, the RAC agreed 
to discuss these protocols in order 
to provide both a framework 
for continued discussion of the 
science, safety and ethical issues, 
and a guidance document for this 
area of research.73 The ongoing 
discussions also considered the 
possibility that in utero genetic 
modifications could have germline 
effects.  
In 1998, a public symposium 
at UCLA, “Engineering the 
Human Germline,” considered 
the prospects for HGGM.  The 
symposium explored the social 
and ethical dilemmas raised by the 
technologies, and gave members 
of the public in attendance the 
opportunity to express their 
views.74,75
In 2000, the AAAS issued a 
report, Human Inheritable Genetic 
Modifications: Assessing Scientific, 
Ethical, Religious, and Policy 
Issues.  The report concluded that 
HGGM could not at that time be 
carried out in humans safely and 
responsibly and that few scenarios 
existed in which HGGM would be 
the only option to prevent genetic 
disease in one’s offspring.  The 
report also stated that the impact 
of HGGM on future generations 
raises serious ethical concerns 
because of its potential to alter 
attitudes towards human beings, 
the nature of reproduction, and the 
parent-child relationship, as well as 
its potential to exacerbate existing 
societal inequalities – particularly 
if HGGM were used to “enhance” a 
child rather than avoid a serious or 
fatal disease.34
Among its recommendations, 
the report noted the absence of 
sustained public deliberation on 
the subject and the need for such 
deliberation to occur in advance 
of technological possibility in 
order to influence whether, how, 
and to what extent HGGM moved 
forward. The report echoed 
the Presidential Commission’s 
recommendation that public 
oversight and public discussion 
were necessary.  It recommended 
creating both a public body to 
monitor and oversee research 
developments in HGGM as well 
as a mechanism for assessing 
short and long term risks and 
benefits, before any protocol moves 
forward. The report stressed that 
society would need to determine 
whether HGGM would be socially, 
ethically, and theologically 
acceptable.  Finally, the report 
recommended that public funding 
should not support clinical 
development of technologies for 
HGGM until a system of oversight 
is in place.34
Most recently, the President’s 
Council on Bioethics briefly 
addressed HGGM.  In its report 
Reproduction and Responsibility, 
the Council describes the safety, 
ethical, and regulatory issues 
related to HGGM while strongly 
emphasizing that HGGM is purely 
speculative “for now, and for the 
foreseeable future.”76  
What Does the Public Know and 
Think about HGGM?
As described in the previous 
section, the most visible 
deliberation about HGGM 
has been confined to elite 
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governmental commissions or 
scholarly groups. These same 
entities frequently have called for 
a broader public input into what, 
if any, use of HGGM might be 
appropriate.77,78 Yet, until now, 
little has been known about what 
the American public knows or 
thinks of HGGM.  
Much of the American public 
has had little access to accurate 
information about HGGM.  
Instead, “information” about 
HGGM has come from Hollywood 
in the form of disquieting, 
sometimes horrific portrayals 
of the results of irresponsible 
scientific tampering or accidental 
mishaps (see box).
Most films and television 
shows play upon the public’s 
fears of scientists running amok 
and the erosion of liberty in the 
name of technological progress.  
The popular press also sends 
strong messages to the American 
public about HGGM.  In a 2003 
Time Magazine cover story 
celebrating the 50th anniversary 
of the discovery of DNA, seven 
prominent scholars speculated 
about how genetics will change our 
lives. Each presented an optimistic 
vision of a future in which genetic 
knowledge and manipulation lead 
to longer, healthier lives.79 With 
genetic breakthroughs reported 
almost weekly, some view media 
reports as overwhelmingly 
positive and have criticized the 
media for building unreasonable 
expectations about the potential of 
genetics to transform our lives.80,81 
Some comments reported by the 
media have been particularly 
extreme.  James Watson, one of 
the co-discoverers of DNA, said 
in 2003 that intelligence and 
appearance were fair game for 
germline genetic modification:  
“People say it would be terrible if 
we made all girls pretty.  I think it 
would be great.”82
How has the public absorbed 
these messages?  Is HGGM 
something to be feared? Or does 
the public believe that genetic 
modification holds great promise 
for health and happiness?  In 
order to better understand the 
public’s attitudes, hopes, and 
concerns about HGGM and other 
reproductive genetic technologies, 
the Genetics and Public Policy 
Center conducted an ambitious 
research project including 
surveys, focus groups, and 
interviews.83,84,85,86  
 
The public’s views of HGGM do 
not necessarily reflect the extreme 
messages from the entertainment 
industry or media.  In our focus 
groups and interviews, members of 
the public show significant interest 
in HGGM’s potential to provide 
treatments and cures. 
HGGM at the movies
In the 1982 film “Blade Runner,” genetically enhanced humanoids 
known as “replicants” were created to colonize distant plants.  But 
society’s obsession with creating a better human being backfired.  After 
a bloody mutiny on an off-world colony, replicants are declared illegal 
and terminated upon detection. 
In the 1997 film “Gattaca”, individuals who are not genetically ideal are 
relegated to a lower status and face discrimination in many forms.  The 
lead character must purchase the identity of a genetically perfect human 
in order to have any hope of rising beyond his lowly position in society.  
Recent film versions of the Spiderman comic departed from the Marvel 
comic original. In these stories, a genetically modified spider bites Peter 
Parker and gives him all his powers.  
The television show “Mutant X” is Hollywood’s latest foray into the 
world of HGGM.  In this drama, a geneticist accidentally creates 
genetically modified humans with superpowers.  He must fight to 
protect these misunderstood superheroes from those who would destroy 
them.
Human genetic modification even makes an occasional appearance in 
children’s shows, such as the Disney films and television cartoons “Lilo 
and Stitch.” The likeable but destructive character Stitch is the product 
of a genetic experiment by a mad scientist in outer space.  Stitch crash 
lands on Hawaii and is befriended by a young human child, Lilo.  Stitch 
and his other friends from the experiment wreak havoc while the three-
eyed alien mad scientist attempts to contain them.  
Ethics: Expert and Public Views
30 Human Germline Genetic Modification: Issues and Options for Policymakers
“Well, if we can get rid of 
diseases like cystic fibrosis 
or colon cancer, I think that 
would be wonderful… My 
goodness.  I would have done 
anything to do that if we 
had the chance at the time.” 
(Interview with father of child 
with cystic fibrosis)
“It’s almost just like we are 
eliminating polio, any other 
disease, why wouldn’t I want 
that (HGGM for sickle cell 
disease) for my baby if we 
could do this.” 
(Participant in African 
American male focus group, 
Tennessee)
However, members of the 
public do have fears about the 
development of these technologies. 
Some focus group participants 
specifically raised the specter of 
mad scientists who are willing 
to try anything for fame, and 
biotechnology companies in a 
relentless quest for profit.  
“You are a reasonable person.  
We are responsible people 
here, but some of those 
scientists, because of the 
science and because of their 
warped mind, they will do 
something stupid like that, 
and you know they can, and 
they will.”  
(Participant in Mexican 
Catholic female focus group, 
California)
“[W]ith the medical 
profession, I think…they’re 
brilliant and they do 
amazing things, but some 
of what drives the medical 
community is ego and 
accomplishment.  How do 
you know when they’re going 
to cross that line just because 
they want to be the one?…
[T]hey’re willing to take risks 
or, `Well, I know this one’s 
not going to turn out right.  
I’ll tell them that it will be 
right because the next five, 
by learning what I can from 
this, then five people down 
the road [may benefit].’”  
(Participant in mixed sex/race 
focus group, Massachusetts)
“There are very few people 
who are pure researchers 
who don’t have any financial 
motivation for the success of 
their research.” 
(Participant in Protestant 
female focus group, 
Massachusetts)
Other participants were 
skeptical that the use of HGGM 
would stop at serious medical 
issues.
“I like the idea of this one 
thing [HGGM for cystic 
fibrosis], and maybe a few 
other life threatening, 
horrible disease kinds of 
things, but I know it would 
never stop.” 
(Participant in Evangelical 
female focus group, Colorado)
“It’s all or nothing.  If you’ve 
gone down this road at all, 
you’ve gone down completely.  
You can talk about matters 
of degree, but you’re playing 
God....if we can actually do 
it, I think that’s great.  But 
there is a lot of downside that 
goes with it.  We’re talking 
about the best intentions 
of medicine, and assuming 
that this is all going to be 
for good.  But how many 
movies have we seen [with] 
so many nightmare scenarios 
of people manipulating this.  
So opening that door at all 
means its open, regardless of 
the degree.”  
(Participant in Caucasian 
male focus group, Colorado)
For some focus group 
participants, the long-term impact 
of HGGM raised serious concerns.
 “[W]ho knows the long-term 
effects of doing all this gene 
fixing?  And then, as the 
generations that follow – that 
we created, or whatever – 
what happens with that, their 
DNA’s when they mix? And 
I don’t know – it just seems 
all very difficult and scary to 
some point.” 
(Participant in Mexican 
American female focus group, 
California)
“What if you made a 
correction, what if there was 
an error and you created 
something worse?”  
(Participant in mixed sex/race 
focus group, Massachusetts)
Additional issues, such as access 
to new technologies were also 
important to some participants:
“I mean, obviously this is 
not going to be available 
to everybody, regardless of 
whether it’s subsidized by 
insurance or whatever.  There 
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are going to be some people 
that are able to have super 
kids, or improved kids, and a 
lot that aren’t.”  
(Participant in Caucasian 
male focus group, Colorado)
Some participants discussed the 
use of reproductive technologies 
in terms of the role of suffering in 
people’s lives.  Most view suffering 
as something best avoided, yet 
a few described affliction as an 
important aspect of existence that 
allows individuals, families, and 
society to grow and learn: 
“[E]veryone has got obstacles 
in life to get through, and if 
you terminate all of [these] 
from the very beginning 
to where people have an 
almost perfect existence, that 
eliminates a little challenge 
from life. And having things 
like this … sometimes they 
can give people a reason to 
try harder, or a reason to 
build themselves up to be 
better than they are.” 
(Participant in young male 
focus group, Tennessee)
And finally, concerns were 
expressed about how individuals 
view themselves and their 
children:
“People get caught up in 
making the perfect child. 
You are trying to create the 
perfect life and making the 
perfect child, and that is not 
synonymous.”  
(Participant in African 
American female focus group, 
Tennessee)
“I just still think it goes 
against nature’s way of 
maintaining order and 
balance on the planet. We are 
not meant to have a planet of 
complete, perfect individuals 
that are going to live to a 
hundred years old.”  
(Participant in Mexican 
American male focus group, 
Los Angeles)
The Center’s 2004 survey of 
4,834 Americans found higher 
levels of approval for the use 
of HGGM (as well as other 
reproductive genetic technologies) 
for health-related reasons. In 
general, however, Americans 
appear to be ambivalent about 
HGGM.  For example, 57 percent 
approved of HGGM to avoid fatal 
childhood disease while 19 percent 
approved of the use of HGGM 
to have children with desirable 
“traits” (Figure 6).  
For What Purpose?
There are multiple potential 
uses for HGGM if it becomes 
technically possible.  HGGM 
could “fix” an inherited genetic 
disease before a child is born, and 
prevent the passing of the disease 
to future generations.  These uses 
often are referred to as therapeutic 
or health-related, although the 
exact meaning of these words 
often depends on who uses them.  
HGGM also could be used for 
enhancement, to create children 
with particular genetic “traits” 
desired by the parents – traits that 
are not necessary for good health 
but that are perceived as enhancing 
the child.  Again, the exact 
meaning of many of these terms 
and the lines between disease and 
trait are far from clear. 
The availability of alternative 
reproductive technologies such 
as PGD, and the technical 
impediments to HGGM have 
meant that for many years 
HGGM has been what bioethics 
professor Eric Juengst has called a 
“bioethicists’ problem.” Given the 
many alternatives for addressing 
genetic disease, it seems HGGM’s 
usefulness would be limited to 
enhancement purposes, which 
are widely regarded as unethical.  
Discussing policy schemes to 
regulate research and assess 
risks and benefits sometimes 
has been seen as prematurely 
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Figure 6: Americans’ Approval 
of HGGM
Source: Survey 2004
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encouraging questionable uses of 
the technology.87 
Some policy schemes would 
make any germline techniques 
or enhancement uses off-limits 
and would allow only therapeutic 
use of somatic gene transfer.13,92,94 
However, possible inadvertent 
germline effects have been 
reported in somatic gene transfer.95 
Some suggest such effects should 
be considered in context of the 
severity of the disease that is being 
treated, and should not necessarily 
preclude scientists from developing 
effective somatic treatments (see 
arrow A in Figure 7).96
In addition, some scientists 
believe HGGM will be a more 
effective way of accomplishing the 
therapeutic goals of somatic gene 
transfer. For example, geneticist 
Mario Capecchi has argued that 
intentional germline methods will 
be more efficient and effective than 
somatic methods at delivering new 
genetic material to an adequate 
number of cells to produce the 
desired therapeutic effect.97 If true, 
intentional germline approaches to 
enhancement, such as improving 
intellect or strength, may also 
be more effective than somatic 
approaches.  In sum, germline 
modification could occur as a 
means to or side effect of somatic 
modification (see arrow A in 
Figure 7). 
The line between using HGGM 
for therapeutic, or improved health 
purposes, and using HGGM for 
non-health related, or 
“enhancement” purposes, also is 
difficult to draw.  In the context 
of somatic gene modification, 
scientists already have succeeded 
in creating mice and rats that 
have 20%–30% greater muscle 
mass, recover from injury more 
quickly, and live longer than 
normal mice, changes that could 
be viewed as enhancement rather 
than therapeutic98,99 (see arrow B in 
Figure 7).  HGGM could be used 
for overall health enhancement 
rather than to prevent a particular 
known inherited disease such as 
sickle cell disease. For example, 
prospective parents might be able 
to provide their offspring with 
heightened immunity to disease 
through a germline “vaccine” 
against conditions such as HIV 
(see arrow C in Figure 7).100   
The intentional replacement of 
ooplasm containing mitochondria 
and mtDNA may be a therapy for 
rare mitochondrial disease (Figure 
3).  This would be a therapeutic 
use of HGGM.  But, it is also 
possible to imagine using a similar 
technique for enhancement: 
mitochondria, which control 
the cell’s energy levels, could be 
manipulated in an attempt to 
boost a person’s overall energy 
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Figure 7: HGGM for What Purpose? The Challenge of Drawing Lines
This figure is based on slides presented by Eric Juengst at the Genetics and Public 
Policy Center’s “Babies By Design” meeting.  Leroy Walters, W. French Anderson and 
others also have mapped the possible purposes for HGGM.88,89,90,91,92,93
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If, in the future, genes that 
significantly influence appearance 
or intelligence are identified, 
some prospective parents 
may be interested in using 
HGGM to pursue these traits 
in their offspring and future 
descendants.101 Whether or not 
society officially deems such 
uses appropriate, determined 
prospective parents might be able 
to find providers willing to help 
them pursue such goals. 
These potential uses suggest 
that the traditional framework 
of dividing the uses of HGGM 
between “therapy” and 
“enhancement” may be too 
limited.  It has been argued that 
an additional category, prevention, 
could include the use of HGGM to 
prevent disease by enhancing the 
body’s natural immunity.13,102,103
 
However, depending on the user 
and the context, “prevention” may 
be difficult to define.  Prevention 
could include interventions to 
prevent a genetic disease that is 
certain to develop, which may be 
indistinguishable from therapy.  It 
might include preventing diseases 
that are the result of natural and 
universal processes like aging, 
strengthening the body in ways 
that seem superhuman, which 
may be indistinguishable from 
“enhancement.”13,92 And HGGM 
sometimes may be viewed not 
as “preventing” a disease in an 
individual but as preventing the 
birth of the original individual 
by changing who that individual 
is with the goal of reducing or 
eliminating the occurrence of the 
disease in a population.102 
Playing God
Some argue against HGGM 
by equating it to “playing God” 
and interfering with life as God 
intended it to develop. Paul 
Ramsey, a prominent theologian 
in the 1960’s and 70’s argued, 
“Men ought not to play God before 
they learn to be men, and after 
they have learned to be men, they 
will not play God.104 Theological 
discussions about HGGM often 
turn on the question of whether 
new technologies such as HGGM 
further God’s will or attempt to 
usurp it.  
However, in some religious 
traditions, such as Judaism and 
many Protestant traditions, the 
notion of playing God is not 
necessarily negative.105 Rather, 
the belief is that human beings 
act as partners with God, taking 
responsibility for the pursuit of 
healing.106 Some theologians argue 
that new technologies may be 
consistent both with theological 
conceptions of humans as co-
creators and with more secular 
ideas about moral duties to 
promote human flourishing and 
well-being.107  
Impact on Human Dignity
Human dignity is a difficult 
quality to define.  Leon Kass, 
chair of the President’s Council on 
Bioethics, has referred to it as “that 
elusive core of our humanity … 
the profoundly special character 
of human beings and the special 
virtue to which we may rise.”108 
Dignity may also be seen as 
a quality that enables human 
suffering to be redeemed, that 
drives us to strive on and engage 
in the world. Some view it as a 
human quality bestowed by God 
while others believe it comes from 
society or from our innate nature 
and rational capacity.109,110 
Religious and secular scholars 
alike have argued that HGGM 
would threaten human dignity by 
creating children in a utilitarian 
way, raising questions about 
whether every individual will 
be afforded the dignity he or she 
deserves.52 As the President’s 
Council on Bioethics has written, 
A child who is designed to 
certain specifications might 
be viewed as more of an 
artifact – or more answerable 
to the will of his or her 
parents – than a child who 
is merely selected for his or 
her existing characteristics…
turning procreation into 
a form of manufacture; 
promoting a new eugenics, 
where parents and society 
seek only the ‘best’ children; 
allowing individuals or 
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“I would love to have a child free of 
disease, and…no one gets sick, but 
it’s again, to me, it’s God’s will….The 
negative effect is playing God, and I 
don’t think God is going to like that.” 
Participant in Mexican male focus 
group, California
“It’s the old argument, you know, if 
God wanted you to fly, he’d give you 
wings.  Well, you know, we got past 
that.  We fly now.  You know?”  
Participant in mixed sex/race 
focus group of people over age 55, 
California
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society to alter the native 
human capacities of offspring 
in a direct way, and perhaps 
to engineer novel capacities 
not hitherto present in 
human beings; and binding 
the next generation to a 
genetic fate that suits the will 
of the present one.”111 
HGGM and Eugenics
Eugenics is a term coined by 
Sir Francis Galton in the late 19th 
century to refer to the “study of 
agencies under social control that 
may improve or impair the racial 
qualities of future generations, 
whether physically or mentally.”112 
Galton and his followers believed 
that characteristics such as 
intelligence, wealth, and success 
were hereditary. His theories 
spawned eugenics movements, 
including in the United States, 
during the late 19th and early 20th 
century.  These included programs 
of “positive” eugenics, aimed at 
encouraging those considered to 
have particularly good heritable 
characteristics to have more 
children, and of “negative” 
eugenics, aimed at discouraging 
or actively preventing those 
considered unfit from having 
children. Many states enacted 
laws permitting the involuntary 
sterilization of institutionalized 
persons and 40,000 eugenic 
sterilization operations were 
recorded in the U.S. between 1907 
and 1945.113  One such law was 
upheld by the Supreme Court. In 
Buck v. Bell, Supreme Court Justice 
Oliver Wendell Holmes, Jr. opined 
that those that “already sap the 
strength of the State” must make 
sacrifices to prevent our being 
swamped with incompetence,” 
and reached the now infamous 
conclusion that “three generations 
of imbeciles are enough.”114
The government-sponsored 
eugenics practiced in Nazi 
Germany is the starkest example 
of the implementation of eugenics-
based policies.  Noted scholar and 
member of the President’s Council 
on Bioethics Francis Fukuyama 
has described Nazism as “the last 
important political movement 
to explicitly deny the premise of 
universal human dignity.”115 The 
Nazi “racial hygiene” movement 
espoused the view that the 
Nordic race was genetically ideal 
and that non-Nordic races were 
genetically inferior and weakened 
society. Jews in particular were 
singled out for elimination, first 
through professional and social 
exclusion and then through 
extermination. The Nazis also 
sought to prevent reproduction by 
Germans with those whose genes 
were considered inferior. Under 
the 1933 “Law for the Prevention 
of Congenitally Ill Progeny,” 
which authorized sterilization of 
those with one of nine conditions 
including “feeblemindedness,” an 
estimated 400,000 Germans were 
forcibly sterilized. Additionally, 
an estimated 200,000 Germans 
– including babies with Down 
syndrome and elderly psychiatric 
patients – were killed.113
For some observers, powerful 
parallels exist between the 
eugenics movement of the early 
20th century and HGGM.  Those 
who view HGGM as a form of 
modern eugenics fear it will be 
used to permit only those with 
“ideal” genes to come into being.  
They worry that the allure of 
what the Council for Responsible 
Genetics calls “biological 
perfectibility” will result in 
organized eugenics programs.116 
As the President of the American 
Association of People with 
Disabilities has stated:
 “One would hope that 
reactions to the Holocaust 
and the advent of the 
disability rights and 
independent living 
movements in the U.S. and 
around the world would 
have put an end to the 
eugenic efforts to eliminate 
people with disabilities…. 
Unfortunately, if we examine 
the rhetoric of some 
influential modern scientists 
and ethicists, we can see the 
emergence of a new eugenics 
tied to the rapid advances in 
scientific understanding of 
the human genome.”117 
Impact on Human Species
Some argue that changing the 
genetic makeup of individuals 
to prevent disease or enhance 
characteristics will change the 
overall genetic composition 
and diversity of the human race 
with unpredictable and perhaps 
disastrous consequences.  For 
example, the Council of Europe 
has stated, “Whilst developments 
in this field may lead to great 
benefit for humanity, misuse of 
these developments may endanger 
not only the individual but the 
species itself.”118 Indeed, health 
problems such as developmental 
syndromes have appeared during 
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genetic experiments with mice: the 
concern is that HGGM similarly 
would alter the “natural order” and 
may result in new genetic diseases 
in humans.51,119 
Others have argued, however, 
that the risks of HGGM to the 
human species as a whole are 
overstated.  They point out that 
every medical treatment or 
procedure that allows people who 
otherwise would have died to 
survive and reproduce changes 
what genes would “naturally” 
continue to exist.120 They believe 
that “[t]he whole practice of 
medicine is a comprehensive 
attempt to frustrate the course of 
nature.  If we always preferred the 
natural as a matter of principle, 
we would have to abjure medicine 
altogether.”121 Some add that 
HGGM is “not likely to have a 
significant effect on the human 
gene pool,”13 and that we need to 
keep in mind the baseline level 
of genetic change that occurs 
without human intervention.96 
For example, genetic material 
can change position or “jump” 
in unexpected ways.  One study 
found that one in eight sperm 
contains new genomic sequence 
caused by “normal” movement of 
genetic material.122,123 
Although the intent of HGGM 
may be to improve humans, 
some believe “the outcomes 
will be quasi- human or less 
than human,”119 and those who 
have been altered may lose the 
rights to which they otherwise 
would be entitled.124 However, 
others have argued that it is 
impossible to contemplate truly 
“preserving” the species because 
humans are changing the species 
all the time through medical or 
other interventions.125 As one 
commentator put it, “We are 
all new ‘population variants,’ 
constantly generated by the 
interaction of our genomes and 
epigenomes with the natural and 
technological world.”121 Unless 
HGGM were to become easy, 
inexpensive, efficient, widespread, 
and accessible to many, the 
changes confined to just some 
individuals seem unlikely to affect 
the human race as a whole: “A 
handful of rich people genetically 
modifying their children for 
greater height or intelligence 
would have no effect on species-
typical height or IQ.”126 
Impact on Society
Similar to concerns about 
other reproductive genetic 
technologies, there are concerns 
about the impact of HGGM on 
society, particularly whether its 
use would exacerbate existing 
societal inequalities. HGGM is 
likely to be extremely expensive 
and only those who could afford 
it would benefit.  The most basic 
health care is not available to 
many members of society, and 
inequalities in access mean that 
HGGM would only be available 
to a few, reinforcing or increasing 
existing disparities and widening 
the already existing class divide.127
 A troubling and sinister 
relationship between the 
genetically enhanced and non-
enhanced members of society 
could arise as a result of the 
divide: “Ultimately, it almost 
seems inevitable that genetic 
engineering would move Homo 
sapiens into two separable species: 
The standard-issue human 
beings would be seen by the new 
genetically enhanced neo-humans 
as heathens who can properly be 
slaughtered and subjugated.  It 
is this genocidal potential that 
makes species-altering genetic 
engineering a potential weapon 
of mass destruction and the 
unaccountable genetic engineer a 
potential bioterrorist.”128
There is a rich history of 
discussion about the impact of 
new reproductive technologies on 
people with disabilities.  Many 
have raised concerns about using 
these technologies to prevent 
the birth of babies affected by 
genetic disease, maintaining that 
this trend could make society 
less tolerant of people living with 
disabilities.  Disabilities rights 
advocates also argue that the 
disabilities sought to be prevented 
through technologies such as 
prenatal diagnosis, PGD and 
potentially HGGM, need not be 
considered disabilities at all but 
reflect society’s unwillingness 
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“Well, you know, it’s unfortunate; 
but there probably would be this 
whole competition thing…. people 
perceive that if you are more perfect 
or closer to perfection then you have 
more value as a human being…  And 
we might end up being a society… 
you know, that doesn’t take care 
of everybody but that certain 
individuals have more value than 
other individuals because they’re 
closer to perfection.”  
Interview with mother of child with 
cystic fibrosis
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to accept and accommodate 
people with variations from some 
arbitrary standard of what is 
considered “normal.” 
Modifying children to eliminate 
disabilities conflicts with the 
notion that living with a disability 
need not be detrimental to that 
individual, his or her family, or 
society at large.  Such decisions 
by prospective parents reduce 
a disabled person to a single 
trait and reinforce the idea that 
the problem is disability, rather 
than society’s failure to provide 
adequate measures so that those 
who are disabled can function 
well.130  
Preventing or treating a disease 
or condition in an existing 
individual may be viewed as less 
problematic than using PGD or 
prenatal diagnosis followed by 
abortion to prevent the person 
from existing in the first place.  As 
bioethicist Ruth Faden has written,
[T]reating the prevention 
of the birth of children 
who would have a disease 
or disability as morally 
equivalent to preventing 
illness or disability in persons 
already living involves a 
morally unacceptable view of 
the worth of such persons.  It 
suggests that the lives of some 
persons with a disability or 
illness are not worth living, 
that such persons are to be 
understood only as social or 
economic drains and never as 
sources of either independent 
value or enrichment for the 
lives of others.129 
If HGGM were to be considered 
treatment, then perhaps it is 
more morally acceptable than 
the alternatives.  HGGM may be 
viewed by some as preserving 
the person, rather than rejecting 
the person because of his or her 
disability.131 It might be considered 
a “less odious form of selection 
because it is attempting to provide 
health and capacity to some new 
being rather than excluding from 
coming-into-being a person who 
will have what is considered 
diminished health or diminished 
capacity.”132
Indeed, the disability critique 
of HGGM may change as the 
technology changes.  Decades 
from now, HGGM may be more 
like a treatment for a future 
person, allowing a person to come 
into existence free of disease 
– prospective parents undergo a 
procedure that transforms their 
eggs or sperm, allowing offspring 
to be born “pre-treated” or 
prevented from having a specific 
genetic disease or disorder.  On the 
other hand, if and when HGGM 
first occurs, for many years it will 
undoubtedly require couples to go 
through IVF and create embryos, 
either to perform HGGM on the 
embryos themselves or to make 
sure the HGGM worked before 
proceeding with pregnancy.  Such 
a process, practically speaking, 
would raise the same issues as 
PGD – choosing (and discarding) 
embryos based solely on a genetic 
finding.
Regardless of the techniques, 
prospective parents using HGGM 
to “fix” a future child before 
birth would reinforce the fact 
that society continues to make it 
difficult for individuals and their 
families to live with a disability. 
If and when HGGM becomes 
available, parents may feel social 
and financial pressures to pursue 
it.  Some are concerned that 
insurers may someday demand 
that prospective parents undergo 
any number of measures, including 
HGGM, to prevent the birth of a 
child with genetic disorders.127  
Impact on Families
HGGM has the potential to 
change family relationships. 
Prospective parents may decide to 
pursue HGGM for any number of 
reasons: some because of cultural 
norms or personal opinions about 
what is desirable, others because 
of lack of complete information 
about what HGGM might or might 
not offer.  A modified child, once 
mature enough, may object to the 
changes that were made and resent 
the parents for making them.  
Alternatively, an unmodified child 
may resent not having been given 
the very best genes available.
By changing human 
reproduction in the search for 
“perfect children,” some believe 
germline genetic modification and 
other reproductive technologies 
will change the nature of the love 
parents have for their children by 
making children a commodity 
that parents have produced to 
their specifications rather than 
a gift to be loved “to the point of 
irrationality.”133 This result may 
harm children who, although 
they may be less than “perfect” in 
their parents’ eyes, still need their 
unconditional support.  One fear 
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is that adverse outcomes from 
HGGM that result in children 
born with malformations or 
genetic disease will lead to the 
modified offspring being rejected 
by their families and society and 
becoming “entities distanced 
not only from the physiological 
reproductive process but from 
human forebears with any socially 
prescribed responsibility for 
them”.134 
An opposing argument is 
that parents and society have a 
responsibility to try to bring into 
the world the healthiest possible 
children for the next generation.53 
Parents often make decisions on 
behalf of their children because 
they “want the best for them,” be 
it attempting to change the child’s 
appearance through orthodontia 
or choosing their schools.   Some 
distinguish between wanting to 
give children new “tools” (schools, 
music lessons, orthodontia) 
and trying to change the child’s 
innate capacities.  Erik Parens 
of the Hastings Center has 
distinguished these examples 
of parental intervention: the 
advantages bestowed by new 
“tools” are limited by a person’s 
innate abilities or “draw in the 
genetic lottery” whereas genetic 
manipulation aims to change the 
innate abilities themselves.135 
There are a number of moral 
issues related to parents pursuing 
reproductive technologies to 
“help” their children, whether for 
health or enhancement reasons. 
For some, the willingness to take 
such risks, particularly for non-
fatal or non-serious diseases, 
has been viewed as proof of 
parental attitudes already gone 
awry.  Writing about PGD, which 
raises similar concerns, John 
Kilner, President and CEO of The 
Center for Bioethics and Human 
Dignity, states “The demise of 
unconditional acceptance and 
love that usually exists when a 
parent has a child, whether they 
be healthy or not, does not bode 
well for the inevitable situations 
when other unwanted problems 
arise in a child’s life.”136 These 
concerns are not unique to the use 
of new reproductive technologies 
as people often have children for 
reasons that may be viewed by 
some as the “wrong”: to fulfill their 
own personal desires and meet 
expectations that have nothing to 
do with the individual the child 
wants to become.  
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Most national and international 
policy making bodies that have 
considered HGGM have expressed 
deep concerns about its safety and 
ethical ramifications and have 
taken steps to prevent it.
International 
Approaches
In 1997 the Council of Europe 
issued the Convention for the 
Protection of Human Rights and 
Dignity of the Human Being 
with regard to the Application 
of Biology and Medicine, 
which included the Article on 
Interventions on the Human 
Genome. The Article appears 
to condemn both intentional 
germline genetic modification 
and somatic gene transfer for 
enhancement purposes. It states:
 
“An intervention seeking to 
modify the human genome 
may only be undertaken for 
preventive, diagnostic or 
therapeutic purposes and only 
if its aim is not to introduce any 
modification in the genome of 
any descendants.”164
Also in 1997, the United 
Nations Educational, Social, and 
Cultural Organization (UNESCO) 
adopted a non-binding Universal 
Declaration on the Human 
Genome and Human Rights, 
signed by 186 nations. Article 24 
instructs UNESCO’s International 
Bioethics Committee to study 
“practices that could be contrary to 
human dignity, such as germline 
interventions.”165 The International 
Bioethics Committee of UNESCO 
issued a report in 2003 stating:
 “Correction of a specific 
genetic abnormality in germ 
cells or early stage embryos 
(germ-line intervention) has 
not yet been carried out in 
medical practice.  Because of 
the many technical problems 
and uncertainties about 
possible harmful effects on 
future generations, germ-
line intervention has been 
strongly discouraged or 
legally banned.”166
Many countries, including 
Australia, Austria, Brazil, 
Canada, Costa Rica, Finland, 
France, Georgia, Germany, 
Hungary, Italy, Japan, the 
Netherlands, Norway, Slovenia, 
Spain, Sweden, Switzerland, and 
the United Kingdom have laws 
banning the use of HGGM in 
most circumstances.137 Israel 
has established a moratorium 
that will expire in 2007.  Many 
other countries are considering 
legislation that would ban 
HGGM.137
Federal
The United States Congress 
has not passed any law that 
explicitly addresses HGGM but 
existing laws, notably the Federal 
Food, Drug and Cosmetic Act 
and the Public Health Service 
Act, have been interpreted as 
providing sufficient authority to 
federal health agencies to regulate 
research on human genetic 
modification, sometimes termed 
gene therapy.  Two agencies of 
the Department of Health and 
Human Services, the National 
Institutes of Health (NIH) and the 
Food and Drug Administration 
(FDA), have policies in place to 
govern gene therapy research in 
humans.   Over time, the roles 
and responsibilities of NIH and 
FDA have shifted in response to 
changing circumstances. This 
section briefly traces the history 
of oversight of human gene 
modification, both germline and 
somatic, by these two entities and 
the current oversight functions 
played by each. 
National Institutes of Health 
NIH oversight is limited to 
institutions or researchers that 
receive federal funds, which 
encompasses most academic 
institutions in the United States.  
However, NIH regulations and 
policies often “set the tone” for 
privately funded research. 
In 1974, the NIH established 
the Recombinant DNA Advisory 
Committee (known as the “RAC”). 
The impetus for establishing the 
RAC was not human gene transfer; 
indeed, it would be more than 
a decade before the first human 
gene therapy trial took place in 
the United States. Rather, the 
RAC was formed in response to 
public concerns relating to the 
safety of the newly developed 
techniques of “recombinant 
DNA.”138 Initially, the RAC 
focused on safety concerns 
relating to the inadvertent release 
of microorganisms containing 
recombinant DNA into the 
environment.139 In 1976, the 
RAC issued guidelines requiring 
institutions undertaking federally 
funded recombinant DNA research 
to establish an Institutional 
Biohazard Committee for local 
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oversight of such research.140 These 
guidelines have been updated and 
modified over time.141
In 1980, the actions of a 
researcher at the University of 
California at Los Angeles brought 
human gene transfer research 
into the spotlight and led the 
RAC to broaden its scope of 
oversight.  The researcher, who 
was funded by the NIH, conducted 
somatic human gene therapy 
experiments overseas without 
prior authorization by University’s 
institutional review board (IRB).142 
In response to recommendations 
of the President’s Commission 
for the Study of Ethical Problems 
in Medicine and Biomedical and 
Behavioral Research,143 the RAC 
formed the Working Group on 
Human Gene Therapy in 1983.  
The Working Group, which 
included scientists, clinicians, 
lawyers, ethicists, policy experts 
and a representative of the public, 
recommended that the RAC 
broaden its scope to include review 
of protocols for human gene 
transfer. The Working Group also 
drafted over 100 questions relating 
to both science and ethics that 
scientists seeking to conduct gene 
therapy experiments in humans 
would be required to address 
in submissions to the RAC.141 
Consistent with the Splicing 
Life report by the President’s 
Commission, the Working Group 
from its inception took the 
position that it would not consider 
protocols for human germline gene 
transfer.144 
The first somatic gene therapy 
clinical trial occurred at NIH in 
1990.  In that trial, researchers 
used a viral vector to deliver a 
functioning gene for the enzyme 
adenosine deaminase (ADA) to 
a four-year-old girl with severe 
combined immunodeficiency 
(SCID).  As more researchers, both 
academic and industry-based, 
sought to conduct somatic gene 
therapy investigations in humans, 
concerns were raised regarding 
the burdensome and public nature 
of the RAC review process and 
whether NIH was the appropriate 
locus for oversight of gene therapy. 
As FDA assumed a central role 
in the regulation of gene therapy, 
some viewed independent review 
of protocols by the RAC as 
unnecessarily duplicative. Others, 
however, feared that a reduction in 
RAC oversight would threaten the 
safety and public accountability of 
such research.139
The RAC began to redefine 
its role in the mid-1990s and 
moved from independent review 
and approval of individual gene 
therapy protocols to considering 
the ethical implications of new 
applications of human gene 
transfer.  For example, in 1997, 
NIH sponsored a conference to 
discuss the use of gene therapy 
for “enhancement,” meaning non-
life-threatening conditions such as 
baldness.145   
Currently, gene therapy 
protocols funded by NIH or 
conducted at or sponsored by 
NIH-funded institutions must 
be submitted to the RAC, and 
NIH maintains a registry of these 
protocols. Submission to the 
registry is voluntary for protocols 
funded solely with private funds 
and not conducted at or by an 
institution receiving NIH funding. 
The RAC reviews protocols to 
determine if they raise novel issues 
and facilitates public discussion 
of such protocols.146  For example, 
in 1998, the RAC discussed two 
“pre-protocols” for in utero gene 
transfer experiments designed to 
treat SCID and thalassemia.  The 
RAC considered the possibility 
that in utero genetic modifications 
could have germline effects.  
In discussing these protocols, 
the RAC sought to (1) provide 
a “framework for continued 
discussion” of the science, safety, 
and ethical issues surrounding 
gene transfer in prenatal medicine, 
and (2) stimulate “the development 
of a guidance document for this 
novel area of research within the 
context of the NIH Guidelines.”147 
In 1999, RAC committee members 
issued a consensus statement 
that while the RAC “continues to 
explore the issues raised by the 
potential of in utero gene transfer 
research,” it is “premature to 
undertake any human in utero 
gene transfer experiment” at the 
present time.148 
The RAC has adopted an 
explicit policy precluding review 
of protocols for human germline 
alteration.  Germline alteration 
is defined as “a specific attempt 
to introduce genetic changes 
into the germ (reproductive) 
cells of an individual, with the 
aim of changing the set of genes 
passed on to the individual’s 
offspring.”144 If the RAC were to 
modify its current policy and agree 
to consider HGGM protocols, 
at least some HGGM research 
likely would be precluded from 
receiving federal funds because 
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of a 1996 Congressional ban on 
federal funding of any research 
in which an embryo is created, 
destroyed, or subjected to more 
risk than is permitted for a fetus in 
utero.245  This ban could limit some 
HGGM research involving human 
embryos to the private sector. 
Food and Drug Administration 
From the early days of gene 
therapy research, FDA has 
consistently maintained that it has 
authority under the Federal Food 
Drug and Cosmetic Act (FD&C 
Act) and Public Health Service 
Act (PHS Act) to regulate clinical 
applications of gene therapy,149 
and this position has never been 
challenged.  In 1984, FDA signaled 
its intention to regulate human 
gene therapy.  According to the 
FDA, “nucleic acids used for 
human gene therapy trials will be 
subject to the same requirements 
as other biological drugs.”150  FDA 
took the position that gene therapy 
is not fundamentally “different” 
from other types of therapies 
and thus would not require new 
oversight mechanisms. 
Since 1984, FDA has 
communicated the regulatory 
requirements for gene therapy 
through a series of increasingly 
detailed notices and “guidance 
documents.”151 Guidance 
documents are not legally binding 
on the regulated industry.  
However, because these documents 
reflect FDA’s most current 
interpretation of its statutory 
authority, the regulated industry 
often views them, as a practical 
matter, as having the force of law.
In 1991, the Center for Biologics 
Evaluation and Research (CBER), 
the part of FDA that oversees 
gene therapy, told manufacturers 
which scientific issues and safety 
concerns FDA believed were 
important to take into account in 
manufacturing and testing gene 
therapy products.152 
In 1993, FDA issued a notice 
in the Federal Register further 
explaining the legal basis for its 
regulation of gene therapy.153 
The document reiterated that 
existing FDA statutory authorities, 
“although enacted prior to the 
advent of ...  gene therap[y], are 
sufficiently broad in scope to 
encompass these new products and 
require that areas such as quality 
control, safety, potency, and 
efficacy be thoroughly addressed 
prior to marketing.”  The 
document defined gene therapy 
as “a medical intervention based 
on modification of the genetic 
material of living cells.” Such 
cells “may be modified ex vivo for 
subsequent administration or may 
be altered in vivo by gene therapy 
products given directly to the 
subject.” The genetic manipulation 
“may be intended to prevent, treat, 
cure, diagnose, or mitigate disease 
or injuries in humans.” According 
to the document, “[f]inal products 
containing the genetic material 
intended for gene therapy are 
regulated as biological products 
... or as drugs …”153 In other 
words, the regulated “product” of 
gene therapy is the DNA that is 
administered to the patient and 
the delivery system (e.g., virus) 
used to transport that DNA. As 
a result, these generally require 
the premarket submission of an 
application and approval of such 
application by FDA before they 
may be used to treat patients. 
FDA oversight of somatic or 
germline gene therapy requires 
that the researcher submit an 
“investigational new drug” (IND) 
application with preclinical 
(e.g., animal or laboratory) 
data sufficient to justify use of 
the product in humans. The 
IND rules also require that the 
researcher has obtained approval 
from an Institutional Review 
Board (IRB). Since the death of 
gene therapy research subject 
Jesse Gelsinger in 1999, FDA and 
NIH have taken additional steps 
to protect participants in gene 
therapy trials.154,155,156  Currently, 
FDA oversees approximately 210 
active INDs for somatic cell gene 
therapy studies.159 FDA has not yet 
approved for sale any human gene 
therapy product.
In 2001, after the birth of 
children following ooplasm 
transfer (Figure 3), FDA sent a 
letter to researchers asserting 
broad FDA authority over research 
in human “involving the transfer 
of genetic material by means 
other than the union of gamete 
nuclei.” This included the transfer 
of genetic material contained in 
cell nuclei and ooplasm, which 
contains mtDNA.  The letter 
further stated that this research 
requires the submission of an 
IND.”160 
Thus, FDA has made clear that 
it will regulate HGGM.  It is not 
possible, however, to know for 
certain whether FDA has received 
any INDs for germline genetic 
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modification or what criteria the 
agency would use to review such 
applications.  
Federal Human Subject 
Research Protections
All institutions receiving federal 
funds are required to follow federal 
rules to protect human subjects 
of medical research.161 Research 
conducted pursuant to an IND 
or to support an application for a 
new drug or biological product is 
also subject to these regulations.  
The regulations include review 
of research protocols by an 
Institutional Review Board (IRB), 
informed consent of the research 
subject, and periodic reporting.  
Because HGGM research would 
require an IND, and might occur 
at a federally funded institution, 
it would be subject to these 
requirements. 
State Laws
No states regulate somatic or 
germline genetic modification 
directly. However, existing laws of 
more general applicability could 
indirectly affect HGGM research. 
First, laws prohibiting research 
with human embryos could limit 
HGGM research. Currently, laws 
in several states prohibit embryo 
research. In a few instances 
such laws have been challenged 
successfully as unconstitutionally 
vague and/or unconstitutionally 
interfering with procreative 
liberty.162,163 
Second, research subjects who 
believe they were injured as a 
result of participation in HGGM 
research could sue the researchers 
and the institution at which the 
research took place under a variety 
of state or common law principles, 
such as negligence. No court has 
had occasion to issue an opinion in 
this area.
Professional Guidelines
Medical and scientific 
professional organizations are a 
potential source of oversight for 
the research, development, and use 
of germline genetic modification.  
For the most part, professional 
guidelines are voluntary, 
sometimes serving an exhortative 
role, setting the standard for 
appropriate conduct by providers.  
To date, no professional guidelines 
for HGGM have been developed. 
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HGGM is not yet possible, 
nonetheless there has been 
considerable discussion of the 
scientific, ethical, and safety issues 
that surround it, and a number of 
recommendations have been made 
for specific policy changes.34,69 
In this section, we present policy 
options that respond to the many 
divergent perspectives regarding 
HGGM.
For some, the appropriate 
policy choice is clear and simple: 
HGGM should be banned. Those 
holding this view are motivated 
by either the perceived physical 
risks or ethical risks posed by the 
technology, or both. Therefore they 
support policies to ensure that 
HGGM is not attempted.
Others believe there may be 
acceptable uses of HGGM in the 
future, but want to be sure that 
appropriate limitations are set, 
through government or other 
oversight, to ensure safe and 
ethical use.  
Still others want to encourage 
innovation in HGGM. From 
this perspective, regulation, if 
any, should allow prospective 
patients and scientists considerable 
autonomy to move forward in 
attempting germline modification 
in humans.
Ban it
At the present time, the safety 
risks of attempting HGGM greatly 
outweigh the benefits, leading 
many to conclude that an outright 
ban is warranted.  In addition, 
many alternatives to HGGM, 
including PGD, would often 
allow prospective parents to have 
children free of inherited genetic 
disease.  Given these alternatives, 
some proponents of a ban assume 
the technology’s primary use 
would be to create “designer 
babies” with enhanced attributes 
or capabilities, and argue that most 
Americans view this application as 
inappropriate, with the potential 
to alter social relationships and 
society as a whole in a dramatic 
and negative manner.  Further, 
advocates of a ban argue that the 
benefits to the few couples who 
might desire to use HGGM to 
avoid serious genetic disease need 
to be weighed against the safety 
concerns and the risks to the 
future of humanity.  Based on this 
calculus, they conclude that the 
risks of HGGM are too great to 
allow it to develop at all.167
In the United States, several 
approaches could be used to 
ban HGGM.  Congress or state 
legislatures could pass a law 
explicitly prohibiting HGGM 
and imposing penalties on those 
who attempt it.  Congress could 
also enact prohibitions of limited 
duration, imposing “sunset 
clauses” that would require 
reauthorization of the ban at some 
point in the future. 
FDA could articulate a policy 
not allowing clinical research 
using HGGM to proceed. 
While it appears that FDA has 
not yet received any proposals 
for HGGM, there may come 
a time when researchers seek 
FDA authorization for clinical 
research, and an explicit policy 
would provide clarity in such 
circumstances. 
Supporters of a U.S. ban on 
HGGM point to prohibitions 
enacted in other countries as 
examples of sound policy and 
would like to see Congress pass a 
similar law.  Some suggest that an 
international approach would be 
preferable because it would provide 
the most comprehensive protection 
from changes to the human 
species, ensuring that countries 
would reinforce each other’s 
prohibition in this area.  
The United Nations could 
play a role in implementing a 
ban through an international 
convention against HGGM.167 
George Annas, a professor of law 
at Boston University, and others 
have drafted a “Convention on 
the Preservation of the Human 
Species” and have advocated for 
its adoption by the members of 
the United Nations.  Such a treaty 
would ban “species-altering” 
activities, including human 
reproductive cloning and human 
germline genetic modification.  
This approach aims to preserve 
the “human species” globally by 
preventing scientists interested in 
pursuing these technologies from 
seeking a “home country” with the 
most permissive laws.124 However, 
a truly universal ban ultimately 
may be impossible: one country 
permitting the technology could 
provide a refuge for those who 
wish to develop or use HGGM. 
Several critiques of the 
international approach have been 
raised. As a practical matter, it may 
be difficult to obtain support from 
a sufficient number of countries. 
Even those countries that do sign a 
treaty may not comply with it and 
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there is limited ability to enforce 
these agreements because there 
are few international enforcement 
mechanisms.  In addition, a one-
size-fits-all policy ignores unique 
social and political characteristics 
that may dictate approaches that 
best fit a particular country. 
One challenge to crafting an 
effective ban would be defining 
the technology at issue.  Some 
countries have laws that purport 
to ban HGGM but leave enormous 
loopholes. For example, Finland’s 
law states: “Research on embryos 
and gametes for the purpose 
of developing procedures for 
modifying hereditary properties 
shall be prohibited, unless the 
research is for the purpose of 
curing or preventing a serious 
hereditary disease.” It is unclear 
when the exception for “curing or 
preventing a serious hereditary 
disease” would apply.168
The challenges to instituting 
a ban on HGGM are significant 
but those who support a ban do 
not believe them insurmountable, 
particularly given the potential 
harms they foresee if HGGM is 
permitted. 
  
An alternative to governmental 
prohibition is a voluntary 
agreement by scientists that they 
will not pursue germline genetic 
modification in humans. Such a 
consensus would be difficult to 
achieve and virtually impossible to 
enforce.
Regulate HGGM to Ensure Safe 
and Ethical Use
Oversight of HGGM could be 
aimed at ensuring the safety of the 
technology, its ethical use, or both.
Under current law, the FDA 
may have adequate authority to 
effectively oversee the safety of 
HGGM. The agency can require 
review and approval of an IND 
for any HGGM attempt, but 
deliberations are not open to 
the public.  The agency could 
create an advisory committee 
specifically to inform its review 
of HGGM proposals.  FDA 
advisory committees typically 
include researchers, clinicians, 
patients, caregivers, industry, and 
consumers and their meetings are 
open to the public. Creating such 
a committee to consider HGGM 
would give the public more access 
to the deliberations that inform 
FDA decision making, and would 
provide FDA with expert opinion 
and insight regarding the public’s 
concerns. FDA frequently makes 
use of such committees. For 
example, when scientists reported 
the birth of babies resulting 
from ooplasm transfer, FDA 
asked an advisory committee to 
consider this issue, and solicited 
presentations on ethics as well as 
safety and effectiveness.169   
With input from an advisory 
committee, FDA could develop 
additional guidance concerning 
the type of data they would 
require in an IND application to 
study HGGM. The issuance of 
guidance documents would be 
consistent with FDA’s approach 
to other developing technologies; 
indeed, FDA has issued numerous, 
progressively more detailed 
guidance documents for somatic 
gene therapy research to keep pace 
with new developments. 
In addition, FDA could 
address the long-term outcomes 
of children born after HGGM 
and the well-being of future 
descendants.  Longitudinal studies 
could be mandated federally as 
part of IND approval, and could 
receive federal funding as well.  
Such studies would provide critical 
data about potentially harmful 
effects of HGGM, but could 
raise confidentiality concerns, 
depending on how information 
is collected and maintained. 
In addition, the feasibility of 
following patients and their 
descendents for generations is 
uncertain, and current regulations 
would prohibit the government 
from mandating participation. 
Any guidance FDA develops 
could clarify what human research 
subject protections it would apply 
to the area of HGGM and what 
standards IRBs should apply 
as well.  Law professor Rebecca 
Dresser suggests that a new 
HGGM-specific human subjects 
research protection policy is 
needed.49  
In contrast to the FDA, whose 
processes and deliberations 
are largely private and focus 
primarily on safety and efficacy, 
the RAC’s deliberations are public 
and include consideration of 
other ethical and societal issues.  
However, the RAC’s current 
policy is not to consider germline 
proposals.  If this policy were to 
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change, the RAC could function 
as a forum for discussing the 
social and ethical issues raised by 
HGGM, as it has for somatic gene 
transfer research. 55,170 
However, even if the RAC did 
consider germline proposals, it 
no longer has the authority to 
approve them, with the exception 
of those funded by NIH. Moreover, 
the RAC is inherently limited in 
its capacity to oversee research 
not funded by NIH. Thus some 
have suggested that an alternative 
oversight body may be necessary, 
particularly to consider ethical 
issues related to HGGM.55,110
Chief among the ethical 
questions about HGGM, perhaps, 
is the purposes for which it should 
be permitted.  For example, 
HGGM could be permitted for 
non-medical, enhancement 
reasons.  Conversely, HGGM could 
be reserved only for illnesses that 
are fatal or deemed serious.  An 
entity overseeing ethical use would 
need to consider and define what 
uses are permitted under what 
circumstances. Drawing these 
lines would be challenging and 
enforcement probably would be 
difficult. An oversight body would 
need to stay abreast of any new 
proposed uses and what their 
implications might be.
Numerous equity and justice 
concerns have been raised about 
HGGM’s impact on society.  
Many of these concerns implicate 
broader societal and policy 
issues and would be difficult 
to address through policy 
narrowly aimed at HGGM.  
Policymakers could, however, 
explore alternative approaches to 
address these concerns such as 
anti-discrimination laws, better 
access to medical treatment, 
more support for individuals 
and families dealing with genetic 
diseases, and other approaches 
to reduce the perceived need for 
HGGM and concerns about its 
negative impact on society. While 
some might argue that such 
indirect approaches could not 
address meaningfully the many 
societal issues that have been 
raised about HGGM, such reforms 
might provide broader societal 
benefits.  
International bodies such as the 
United Nations also could play a 
role in the oversight of HGGM by 
convening interested stakeholders 
from around the world and 
considering possible international 
treaties or other restrictions aimed 
at guaranteeing safe and ethical 
use.  However, most countries 
outside of the United States 
that have chosen to address the 
issue of HGGM have banned it 
entirely, making it unlikely they 
would agree to a less-restrictive 
international model.  In addition, 
these international entities have 
limited ability to enforce such 
restrictions.
Finally, those interested in 
HGGM, including scientists 
and prospective parents, could 
develop voluntary guidelines for 
HGGM. Such guidelines, created 
in advance of the technology 
being ripe for consideration by 
FDA and/or RAC, could help 
guide its scientific development 
and proposed uses.  However, 
given their voluntary nature, these 
guidelines are unlikely to satisfy 
those interested in enforceable 
governmental limits.
Questions remain about 
whether oversight of germline 
proposals should be treated any 
differently from somatic genetic 
modification by entities such as 
RAC or FDA, international bodies, 
voluntary societies, or a new entity 
in the future.171 On the one hand, 
germline modification could be 
seen as inherently suspect and 
have to overcome a presumption of 
being unsafe and/or unethical.167,172 
On the other hand, the safety and 
ethical issues could be considered 
in the same manner and by 
the same oversight bodies that 
consider somatic proposals.53
Encourage Innovation
Some believe that HGGM 
holds tremendous promise for 
preventing genetic diseases75 and 
that society should pursue policies 
to promote or encourage successful 
HGGM in the future.  Currently, 
governmental funding supports 
animal research that could be 
used to support an application to 
investigate germline modification 
in humans. Although not 
undertaken in pursuit of HGGM, 
this research provides data that 
has helped overcome some of the 
technical obstacles to HGGM.  
Increased funding for such 
research could provide additional 
data that could help lead to 
HGGM in the future. In addition, 
policymakers could consider 
funding research explicitly to 
advance HGGM techniques.  
However, for many Americans, 
new funding of HGGM research 
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would be profoundly disturbing, 
particularly in the absence of 
clearly stated and widely accepted 
objectives for the uses of this 
technology. 
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Despite widely divergent policy 
options to address HGGM, there 
is some agreement among experts 
and the public alike on several 
issues that will need attention in 
the future.  
Many questions remain 
about the safety and potential 
uses of HGGM.  Considerable 
research would be needed to 
demonstrate HGGM’s safety, 
if society chooses to allow it to 
occur.  Much is unknown about 
the potential market for this 
technology and what the effect of 
limitations or oversight might be 
on forces pushing for or against 
the technology.  For example, is 
it more likely that insurers will 
demand that families use HGGM 
to avoid having children affected 
by genetic disease – or more likely 
that insurers will refuse to pay 
for it, leaving HGGM only in the 
hands of the rich who can pay for 
it themselves?  
Constructing policy that reflects 
and is responsive to public opinion 
requires greater attention than 
has been paid thus far to what 
the public thinks about HGGM.  
There is a rich and robust history 
of deliberation about HGGM 
among the experts, with far less 
opportunity for the public to weigh 
in, despite many calls for more 
formal public engagement. 
Some participants in the 
Center’s “Babies By Design” 
meeting that helped inform 
this report expressed the view 
that the fears of the public 
have been underestimated and 
undervalued, even laughed at, 
by those at the forefront of the 
debate.173,174 Decision making 
about human germline genetic 
modification historically has 
been entrusted to government 
advisory commissions.  Sociology 
professor, John Evans argues that 
these entities require a “formally 
rational type of argumentation of 
bioethicists”175 and that the tone 
and structure of the discussion 
within these government bodies 
precludes some from participating 
fully in the public debate. Evans 
argues that those who tend to 
support technologies such as 
HGGM, such as scientists and 
bioethicists, are better able to 
participate in such forums than 
those whose concerns come across 
as more emotionally or morally 
based, including theologians and 
those whose opposition to the 
technology does not fit neatly into 
a model of “calm unemotional 
logical discussions.”176 Thus the 
conclusions of government bodies 
may not, in the end, reflect a broad 
array of viewpoints. 
It is clear that the “experts” 
and the “public” need better 
opportunities in which to share 
and compare views.  Discussions 
of HGGM would benefit from 
input from more voices, including 
patients, families of those 
living with genetic disease, and 
organizations focused on a range 
of issues including civil rights, 
women’s issues, the environment, 
business interests and religious 
concerns. In planning the 
Center’s 2004 “Babies By Design” 
meeting, it became clear that few 
organizations had considered, or 
were willing to discuss publicly, 
what the impact of HGGM might 
be on their constituents. All 
of these groups need a way to 
educate themselves and consider 
the possible risks and benefits 
of HGGM. Open and public 
deliberation should occur before 
new policies are implemented, and 
excellent models exist for inclusion 
of divergent views in productive 
discussion.177  
Although HGGM remains on 
the distant horizon, advances in 
technology are bringing HGGM 
from the imaginable to the 
possible. Thus, this is a propitious 
time to consider the most difficult 
questions about HGGM.  Will we 
attempt HGGM – or work to ban 
it?  What government entities are 
most appropriate for an oversight 
role – and what oversight is most 
appropriate? An enriched and 
expanded discussion that includes 
the “experts” and the “public” 
offers an opportunity to share 
information and understanding 
about the underlying values 
and concerns that inform 
our individual and collective 
perspectives on HGGM. 
Conclusion
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